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Abstract
The Role of Post-Translational Modifications in the Fate of Nascent Tail-Anchored
Membrane Proteins
Jacob Andrew Culver
2021
Membrane proteins contain hydrophobic transmembrane domains (TMDs) which
reside in the nonpolar section of cellular membranes. The synthesis of the majority of
membrane proteins in eukaryotes is routed through the co-translational insertion pathway.
As they are translating nascent membrane proteins, ribosomes are delivered to the
endoplasmic reticulum (ER) where the new membrane protein is co-translationally
inserted directly into the membrane as it emerges from the ribosome exit tunnel. Thus,
newly translated hydrophobic TMDs are never released into the aqueous cytosol.
However, exceptions to the co-translational insertion route exist. Certain membrane
proteins are released into the cytosol and must be captured by chaperones and targeted to
a membrane for post-translational insertion. One class of proteins that require posttranslational membrane insertion is tail-anchored (TA) membrane proteins. As their name
suggests, TA proteins contain a single TMD at their carboxy (C) terminus. When the
TMD of a nascent TA protein emerges from the ribosome exit tunnel, it cannot be routed
for co-translational insertion because translation has already terminated.
Thus, TA proteins containing hydrophobic TMDs are released into the aqueous
cytosol. Such exposed hydrophobicity can trigger nonspecific protein-protein interactions
or protein aggregation, harming healthy cellular function. To address the dangers posed
by hydrophobic TMDs in the cytosol, the TRC/GET chaperone pathways capture, shield,
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and post-translationally insert TA proteins. The mammalian TRC (transmembrane
recognition complex) pathway and the homologous yeast GET (guided entry of tailanchored proteins) pathway are conserved in all eukaryotes.
Although the chaperones and mechanisms that drive nascent TA protein insertion
have been elucidated, how cells recognize and handle exposed hydrophobicity remains
less clear, particularly when comparing misfolded proteins and nascent membrane
proteins. Misfolded proteins are targeted due to their exposed hydrophobicity by quality
control machinery. Since both nascent TA proteins and misfolded proteins contain
regions of exposed hydrophobic amino acids, how do cells accurately distinguish
between TA proteins intended for insertion and misfolded proteins intended for
degradation?
My research published in the Journal of Cell Biology (DOI:
10.1083/jcb.202004086) shows that a portion of nascent TA proteins are ubiquitinated in
the cytosol. Typically, ubiquitination routes a protein for proteasomal degradation.
However, these ubiquitinated TA proteins are properly inserted into the ER and are
deubiquitinated by the homologous deubiquitinases USP20 and USP33. Therefore,
despite both containing exposed hydrophobicity and being ubiquitinated, TA proteins and
misfolded proteins are distinguished from each other within cells as evidenced by their
different fates.
To follow up the novel finding of ubiquitin on nascent TA proteins, I ask what
function this ubiquitination may serve. Does the presence of ubiquitination impact how
TA proteins behave or how they are handled? It appears that nascent TA proteins are well
folded regardless of ubiquitination status. I have found that disrupting the AAA+ ATPase

II

P97 lowers the insertion efficiency of ubiquitinated TA proteins, but not lysine-free (and
thus ubiquitin-free) TA proteins. This may indicate a currently undiscovered role for P97
in TA protein production.
In addition to exposed hydrophobicity and ubiquitination, TA proteins and
misfolded proteins also share machinery such as BAG6. BAG6 acts as a scaffold to bring
TA protein insertion factors together. BAG6 also routes misfolded proteins for
degradation by recruiting the E3 ligase RNF126 to add ubiquitin to misfolded proteins.
Properly balanced protein synthesis and degradation is referred to as protein homeostasis.
Certain environmental conditions or human diseases can disrupt protein homeostasis
leading to the accumulation of misfolded proteins. Therefore, I examined if the
accumulation of misfolded proteins could block TA protein synthesis by occupying their
shared chaperones. Indeed, I observed slower insertion of TA proteins into the ER when
misfolded proteins accumulate. Furthermore, the shared chaperones shift in binding
kinetics and can localize to protein aggregates during stress. Understanding how
misfolded proteins interfere with TA protein synthesis would shed light on the dangers
faced by cells during protein folding diseases and how cells distinguish between
misfolded and nascent proteins under normal conditions.
Lastly, a link between the O-linked glycosylation and TA protein synthesis.
Previously, BAG6 was found to interact with O-linked N-acetylglucosamine transferase
(OGT). OGT adds O-linked glycosylation to proteins. I found that the BAG6-OGT
interaction is sensitive to protein homeostasis stress. Perhaps O-linked glycosylation
assists relevant chaperones in determining the fate of bound substrates i.e., sending TA
proteins to the ER and misfolded proteins to the proteasome.
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Chapter 1: Introduction to membrane protein synthesis,
ubiquitin, and protein degradation
1.1: Synthesis of proteins that span cellular membranes
Eukaryotic cells use phospholipid bilayers, called membranes, to separate
themselves from their environments and to partition various biological functions into
organelles. Membrane proteins embed in or span lipid bilayers to serve vital cellular
functions such as transporting proteins or other molecules across the membrane,
controlling membrane structure, and sending signals/information through the membrane.
Membrane proteins contain one or more hydrophobic transmembrane domains that reside
in the nonpolar/hydrophobic portion of lipid bilayers. These hydrophobic transmembrane
domains (TMDs) create complications for protein synthesis because creating
hydrophobic TMDs in the aqueous cytosol could lead to nonspecific protein-protein
interactions and aggregation as the regions of hydrophobic amino acids are repelled by
the aqueous cytosol.
The main way cells avoid releasing hydrophobic TMDs into the aqueous cytosol
is by routing nascent membrane proteins for co-translational insertion. Membrane
proteins are translated directly into a membrane, so the hydrophobic TMD is never
released into the aqueous cytosol. The process of co-translational insertion begins with
the signal recognition particle (SRP) which binds to hydrophobic stretches of nascent
peptide chains as they are being translated. SRP pauses translation upon binding to a
TMD or signal sequence and then targets the entire ribosome-nascent chain complex to
the endoplasmic reticulum (ER) (Walter and Johnson, 1994). The ER is the organelle
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responsible for the early steps of folding and trafficking nearly all of a cell’s membrane
proteins and secretory proteins. Proteins that route through the ER for their synthesis and
folding account for an estimated third of the human proteome (Braakman and Bulleid,
2011; Kanapin et al., 2003; Kumari and Brodsky, 2021). At the ER, SRP binds to the
SRP receptor (SR) and releases the nascent chain to the Sec61 translocon pore complex.
The nascent membrane protein is translated through the Sec61 translocon (Fig. 1). When
a transmembrane domain is within the translocon, instead of exiting through the pore into
the ER lumen, it is routed through the translocon’s lateral gate into the membrane
(Rapoport, 2007). Thus, cells can synthesize membrane proteins without the risks
associated with releasing a hydrophobic domain into the aqueous cytosol. The membrane
protein is then properly folded and modified with N-linked glycosylation. If the protein is
not an ER resident, then it is further modified at the Golgi apparatus and trafficked to its
intended location via either vesicular transport or cisternal maturation depending on
which trafficking model applies (Malhotra and Mayor, 2006).
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Figure 1: Co-translational insertion shields nascent membrane proteins from the
cytosol.

Figure 1: A model of nascent membrane protein co-translational insertion into the
endoplasmic reticulum membrane. SRP binds the ribosome and the TMD of a nascent
membrane protein and pauses translation. SRP then delivers the entire ribosome-nascent
chain complex to the ER. The nascent membrane protein is then translated into the Sec61
translocon.

1.2: Tail-anchored proteins are an exception to co-translational
insertion.
Exceptions to the rule of co-translational insertion of membrane proteins exist.
Certain membrane proteins must traverse the cytosol to be inserted into the mitochondria,
peroxisome, or ER (Fig. 2). Tail-anchored (TA) membrane proteins are one class of
proteins that evade SRP-mediated co-translational insertion. Tail-anchored membrane
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proteins are defined by having a single TMD at their carboxy (C) terminus (Fig. 3A).
Therefore, the TMD is translated last, so SRP cannot bind to it before translation has
already terminated (Fig. 3B). Thus, TA proteins evade SRP and are translated directly
into the cytosol. Since releasing hydrophobic TMDs into the cytosol carries risks,
chaperone proteins step in to capture and shield the nascent TA proteins. The chaperones
then route the TA proteins for post-translational insertion into the correct membrane.
Multiple different chaperone networks capture nascent TA proteins depending on
the nascent client’s TMD hydrophobicity, TMD length, TMD-flanking amino acids, and
intended destination. The main focus of my research is the GET/TRC pathway. The GET
(guided entry of tail-anchored proteins) in yeast and TRC (transmembrane recognition
complex) in mammals, is a conserved pathway in eukaryotes. The GET/TRC pathway is
the main ER-insertion route for TA proteins, especially those with highly hydrophobic
TMDs (Chio et al., 2017a). There are alternative routes for TA proteins to insert into the
ER. The SND pathway, named for SRP-independent, can direct TA protein insertion
(Aviram et al., 2016). The EMC, ER membrane protein complex, has also been shown to
possess insertase activity (Guna et al., 2018; O'Donnell et al., 2020). Peroxisomal TA
proteins can post-translationally insert directly into peroxisomes via PEX19 and PEX3
(Mayerhofer, 2016). Lastly, the machinery that facilitates TA protein insertion into the
mitochondria is still debated (Drwesh and Rapaport, 2020). However, features of a TA
protein that signal for mitochondrial localization have been found to include a moderately
hydrophobic TMD flanked by positively charged amino acids (Borgese and Fasana,
2011).
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Figure 2: Certain nascent membrane proteins route for post-translational insertion
into various membranes.

Figure 2: Membrane proteins that do not rely on SRP-mediated co-translational insertion
must instead traverse the cytosol to post-translationally insert into target membranes.
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Figure 3: TA protein structure and synthesis

Figure 3: (A) Tail-anchored membrane proteins contain a soluble cytosol-facing amino
(N) terminus and a hydrophobic carboxy-terminal transmembrane domain (C-TMD). (B)
The diagram shows why TA proteins do not follow the SRP-mediated co-translational
insertion pathway seen in Figure 1. SRP cannot pause translation because the TMD of a
TA protein emerges from the ribosome after translation has already terminated.

TA proteins serve a wide variety of necessary functions throughout cells (Fig. 4).
The wide range of essential TA protein functions also means that disfunction of TA
proteins leads to a variety of human pathologies. Mutations in the TA protein Emerin are
associated with Emery-Dreifuss muscular dystrophy (Pfaff et al., 2016). Loss of the TA
protein Otoferlin causes impaired hearing (Vogl et al., 2016). Mutations in TRC40, the
final targeting factor for TA proteins, are associated with early onset Parkinson’s disease
and pediatric cardiomyopathy (Kun-Rodrigues et al., 2015; Verhagen et al., 2019). TA
proteins are a diverse category of proteins in terms of function and related human
disorders, but most TA proteins route through the same pathway for post-translational
insertion into the ER.
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Figure 4: TA proteins serve necessary functions throughout cells.
Tail-anchored
membrane protein
Localization
Function
VAPA
ER
Membrane contacts and lipid exchange
SEC61β
ER
Protein translocation into the ER
VAMP2
Plasma Membrane Vesicle fusion
Syntaxin6
Golgi
Vesicle fusion
Emerin
Nucleus
Nuclear architecture
BCL2
Mitochondria,
Apoptosis
nucleus, ER
ACBD5
Peroxisome
Membrane contacts and pexophagy
Golgin-84
Golgi
Golgi structure
Figure 4: A table showing a variety of TA proteins and their localizations and functions.

1.3: The chaperone network responsible for TA protein insertion into
the ER
The current model of TA protein synthesis (Fig. 5A) has been referred to as a
chaperone cascade due to the multiple hand-off steps and chaperones involved (Cho and
Shan, 2018; Shan, 2019; Wang et al., 2010). In mammals, after release from the
ribosome, an SGTA homodimer captures the nascent TA protein and delivers it to the
BAG6 trimeric complex. The BAG6 trimeric complex is a combination of the three
proteins BAG6, TRC35, and UBL4A. SGTA binds the UBL domain of UBL4A. TRC35
recruits a TRC40 homodimer, and the TA protein is transferred from SGTA to TRC40.
This step is referred to as a privileged-client transfer because other TA-TMD-binding
proteins cannot interfere with this specific transfer to TRC40 (Chio et al., 2017a; Chio et
al., 2019). However, if SGTA binds a substrate that TRC40 does not recognize as a TA
protein, then the substrate is transferred to BAG6 for ubiquitination and degradation
(Shao et al., 2017). This substrate triage by SGTA, BAG6, and TRC40 is a crossroads
7

between protein synthesis and degradation. If transferred correctly, TRC40 will deliver
the TA protein to the ER insertase complex WRB/CAML. There, TRC40’s ATPase
domain activates to provide the energy to insert the TA protein through WRB/CAML
(Fig. 5A).
The yeast homologue for the TRC pathway is the GET pathway (Fig. 5B). There
are direct homologues for each protein involved save for BAG6 (Fig 6). Although the
BAG6-UBL4A-TRC35 complex serves a similar scaffolding function as GET4/5 for TA
handoff to TRC40/GET3. Other possible differences such as the initial TA protein
capture mechanism are still debated. Recently, it was shown that Get4 binds to the
ribosome, and Get5 recruits Sgt2 to allow for capture of TA proteins immediately after
release from the ribosome in yeast (Zhang et al., 2021). How closely this matches the
mammalian TRC pathway is yet to be seen. However, the BAG6 complex, similar to
Get4/5, has been shown to interact with the ribosome (Mariappan et al., 2010). Another
possibility has been proposed for yeast in which SSA1, a member of the HSP70 family,
could be the first to capture nascent TA proteins (Cho and Shan, 2018; Cho et al., 2021).
Though I primarily focus on the mammalian TA protein insertion pathway, understanding
the homologous yeast pathway provides relevant insights.
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Figure 5: Tail-anchored membrane protein insertion pathway
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Figure 5: (A) Stepwise model of the synthesis of TA proteins in mammalian cells.
Dashed arrow represents pathway for substrates not suitable for capture by TRC40. These
substrates are recognized instead as misfolded and are bound by BAG6 which routes
them to the proteasome for degradation. (B) Stepwise model of the synthesis of TA
proteins in yeast.

Figure 6: TA insertion machinery homologues in yeast and mammals
Function

Yeast

Mammals

Early capture chaperone

Sgt2
SGTA
Get5
UBL4A
BAG6
Transfer scaffold
Get4
TRC35
Final targeting and ATPase factor
Get3
TRC40
Get2
CAML
Membrane receptor and insertase complex
Get1
WRB
Figure 6: A table showing the yeast and mammalian conserved TA insertion machinery.
Yeast Get proteins are numbered starting at the membrane and counting back towards the
ribosome. Yeast does not have a BAG6 homologue (Chio et al., 2017a).

There are many interesting structural details that impact the TA insertion
pathway. The amino terminus of SGTA is the site of homodimerization and can bind the
UBL domain of both UBL4A and BAG6 (Fig. 7A and B) (Chartron et al., 2011;
Chartron et al., 2012b; Darby et al., 2014). To progress the insertion pathway, SGTA
binds a noncanonical ubiquitin-like domain on UBL4A, which is not recognized by
typical ubiquitin-binding domains (UBDs) (Xu et al., 2012). Once SGTA binds to
UBL4A and TRC35 has recruited TRC40, then the privileged client transfer can occur.
TRC40 homodimer in a closed state accepts the nascent TA protein and changes into a
10

fully closed confirmation (Bozkurt et al., 2009). Structural studies have shown an alpha
helical lid that aids in fully closing and capturing the tail TMD (Chio et al., 2017b; Chio
et al., 2019). TRC40 delivers the nascent TA protein to the WRB/CAML insertase
complex where the energy from ATP is used to insert the TA protein. The unloaded
TRC40 is then recycled by converting into an open state to release the ADP and accept
new ATP to return to its closed state ready to accept a new TA protein (Fig. 7C) (Bozkurt
et al., 2009).

Figure 7: Structure and function of TA insertion machinery
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Figure 7: Structure and function of TA insertion machinery. (A) Diagram of the
functional domains of SGTA. (B) Diagram of the BAG6 trimeric complex composed of
BAG6, UBL4A, and TRC35. (C) Diagram of the cycle of TRC40/GET3 as it binds ATP
and uses that ATP to drive membrane insertion of TA proteins through the WRB/CAML
complex.

1.4: Ubiquitin-mediated protein degradation maintains protein
homeostasis.
As briefly mentioned above, the TRC pathway can route proteins for degradation
if the client is not well-suited for membrane insertion. Both SGTA and BAG6 can bind
misfolded or mislocalized proteins, so protein degradation is necessary to allow the TA
protein synthesis pathway to function properly. Misfolded proteins are those that fail to
reach their native conformation, and thus have exposed hydrophobic amino acids instead
of properly folding them within a hydrophobic core. Mislocalized proteins are those that
fail to reach their respective membranes during synthesis and contain hydrophobic signal
sequences or membrane domains (Rodrigo-Brenni et al., 2014). Such misfolded and
mislocalized proteins must be efficiently distinguished from well-folded proteins and
then degraded. Protein homeostasis or proteostasis refers to the balance between protein
synthesis and protein degradation and relies on robust folding machinery (Hartl et al.,
2011; Kim et al., 2013). If proteostasis is disrupted by aging, disease, or the cellular
environment, then misfolded proteins accumulate and form protein aggregates which are
harmful to the cell.

12

Proteasomal degradation and autophagy are the two main pathways cells use to
destroy proteins. Selective autophagy is responsible for long-lived or aggregated proteins,
whereas the ubiquitin-mediated proteasome is responsible for the majority of protein
degradation and is my main focus (Gatica et al., 2018; Lilienbaum, 2013). Both pathways
use ubiquitin as a marker for which proteins should be degraded (Kocaturk and Gozuacik,
2018). Ubiquitin is a small protein conserved in eukaryotes, and the process of covalently
binding ubiquitin to a substrate is referred to as ubiquitination. Ubiquitination requires
three enzymes: an E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and
E3 ubiquitin ligase. The E1 enzyme consumes ATP to form a thioester bond between a
cysteine on the E1 and the carboxyl-terminal glycine of ubiquitin (Hann et al., 2019).
This activated ubiquitin is then transferred to a cysteine on an E2 enzyme for delivery to
an E3 ligase. E3 ligases are categorized into three different classes: RING, HECT, and
RBR (Buetow and Huang, 2016). The different classes of E3 ligases have slightly
different mechanisms of ubiquitination. I focus on the RING E3 ligases due to a link to
TA proteins. The RING E3 ligase brings a degradation target and an E2 activated with
ubiquitin together and triggers the transfer of the ubiqtuitin from the E2 onto a lysine on
the substrate (Fig. 8A) (Buetow and Huang, 2016; Ye and Rape, 2009).
An example of ubiquitination in action occurs when HSC70, of the HSP70
chaperone family, binds a terminally misfolded client. The E3 ligase CHIP binds to
HSC70 and begins ubiquitinating HSC70’s misfolded substrate (Kettern et al., 2010).
Additional ubiquitin can be linked to lysines of already attached ubiquitins forming
polyubiquitin chains. Ubiquitin has multiple lysines that can be modified with other
ubiquitins. The lysines (K) of ubiquitin that are modified and how they branch determines
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the function of the polyubiquitin chain. Ubiquitin K48 and K11 branched chains are a
well characterized marker for proteasomal degradation (Yau et al., 2017). After the
HSC70-bound misfolded protein has been decorated with K48/K11 polyubiquitin chains,
BAG1 binds to HSP70 and delivers the complex to the 26S proteasome (Arndt et al.,
2007). The eukaryotic 26S proteasome functions to unfold the substrate and remove any
attached ubiquitin, so the substrate can be threaded through the proteasome core and
degraded (Ye and Rape, 2009). After breaking the peptide bonds of the misfolded
protein, the freed amino acids and ubiquitin are recycled (Fig. 8B).
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Figure 8: Chaperone- and E3 ligase-driven ubiquitination and protein degradation

Figure 8: (A) General model of how ubiquitin is covalently attached to target proteins.
E1 activating enzymes covalently bind free ubiquitin to a cysteine on the E1 enzyme. The
ubiquitin is then transferred to a cysteine on the E2 conjugating enzyme. The E3 ligates
ubiquitin from the E2 onto a lysine of either the substrate or other ubiquitin. (B) Model of
how chaperones assist in protein degradation. The E3 ligase CHIP binds HSC70 to
ubiquitinate substrates. BAG1 bridges HSC70 to the proteasome to allow substrate
release and degradation.
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1.5: TA protein insertion pathway: an intersection between protein
synthesis and degradation
Protein degradation is essential to clear misfolded proteins that may bind SGTA
or BAG6, but how are nascent TA proteins protected from being targeted by quality
control machinery and degraded in the cytosol? Quality control machinery seeks out
exposed hydrophobicity as a marker for misfolded or mislocalized proteins, but nascent
TA proteins also have exposed hydrophobicity in the cytosol. Furthermore, the TA
protein synthesis pathway contains and interacts with protein quality control and
degradation factors. SGTA can bind ERAD substrates and deliver them to BAG6 (Xu et
al., 2012), and substrates unsuitable for tail-anchored insertion are not transferred to
TRC40 and instead are triaged to and chaperoned by BAG6 (Hessa et al., 2011; Payapilly
and High, 2014; Shao et al., 2017; Tanaka et al., 2016). Similar to the HSC70/CHIP
example from Figure 8B, BAG6 chaperones the misfolded protein and recruits an E3
ligase, RNF126, to ubiquitinate the substrate (Krysztofinska et al., 2016; Rodrigo-Brenni
et al., 2014). The ubiquitinated misfolded protein is then delivered to the proteasome for
degradation (Hu et al., 2020; Rodrigo-Brenni et al., 2014).
Interestingly, SGTA actually antagonizes BAG6-mediated triage by stabilizing
misfolded substrates (Leznicki and High, 2012; Wunderley et al., 2014). SGTA competes
with the E3 ligase RNF126 for binding to the BAG6-UBL domain (Krysztofinska et al.,
2016). Therefore, SGTA binding dynamics may protect TA proteins from
BAG6/RNF126-driven degradation. However, such a protection mechanism would
require a way to distinguish misfolded proteins from TA proteins. Distinguishing TA
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proteins from misfolded proteins may be difficult due to relying on the similar
chaperones and both containing exposed hydrophobicity.

1.6: Thesis research into how post-translational modifications affect TA
protein synthesis
I aim to elucidate the ways in which cells distinguish TA proteins from misfolded
proteins and reliably insert the nascent TA proteins. In Chapter 2: Ubiquitination of
nascent TA proteins and the deubiquitinases involved, I find that instead of avoiding
cytosolic quality control factors, a portion of TA proteins are actually ubiquitinated.
Typically, ubiquitination routes proteins for proteasomal degradation. However,
ubiquitinated TA proteins are able to insert and are deubiquitinated at the ER (Culver and
Mariappan, 2021). In Chapter 3: The function of ubiquitination of nascent TA
proteins, I ask how nascent TA ubiquitination might play a role in the insertion pathway.
Is the ubiquitination due to non-specific TA protein recognition by cytosolic quality
control factors, or could the ubiquitination actually be beneficial to the insertion process?
Ubiquitination could possibly affect folding, protein-protein interactions, or the
recruitment of chaperones to handle the TA protein.
In Chapter 4: TA protein synthesis is impaired during protein homeostasis
stress, I examine how the accumulation of misfolded proteins affects TA protein
insertion. Since TA proteins share characteristics and chaperones with misfolded
proteins, could misfolded proteins bind to important machinery and block TA insertion?
Symptoms caused by misfolded protein accumulation would be further exacerbated if
cells could not efficiently produce vital TA proteins. Lastly, in Chapter 5: A link
between TA protein synthesis and O-linked glycosylation, I return to the question of
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how cells recognize and protect nascent TA proteins. Perhaps other post-translational
modifications, such as glycosylation, are playing a role in this pathway in addition to
ubiquitination. The enzyme responsible for the O-linked glycosylation of proteins is Olinked N-acetylglucosamine transferase (OGT). OGT interacts with BAG6, indicating a
possible link between glycosylation and the TA protein insertion pathway. My work has
expanded our current understanding of tail-anchored membrane protein insertion and
provides a unique examination of alternatives to degradation after a protein is
ubiquitinated.
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Chapter 2: Ubiquitination of nascent TA proteins and
the deubiquitinases involved
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2.1: Summary
Dr. Mariappan and I show that shortly after translation, tail-anchored (TA)
membrane proteins can be polyubiquitinated and yet are targeted properly,
deubiquitinated, and inserted into the endoplasmic reticulum. The ER-localized and
homologous deubiquitinases USP20 and USP33 remove nascent TA ubiquitin
modifications. Without USP20/33, ubiquitinated TA proteins accumulate in the ER
membrane.

2.2: Abstract
Numerous proteins that have hydrophobic transmembrane domains (TMDs)
traverse the cytosol and post-translationally insert into cellular membranes. It is unclear
how these hydrophobic membrane proteins evade recognition by the cytosolic protein
quality control (PQC), which typically recognizes exposed hydrophobicity in misfolded
proteins and marks them for proteasomal degradation by adding ubiquitin chains. Here,
we find that tail-anchored (TA) proteins, a vital class of membrane proteins, are
recognized by cytosolic PQC and are ubiquitinated as soon as they are synthesized in
cells. Surprisingly, the ubiquitinated TA proteins are not routed for proteasomal
degradation but instead are handed over to the targeting factor TRC40 and delivered to
the ER for insertion. The ER-associated deubiquitinases USP20 and USP33 remove
ubiquitin chains from TA proteins after their insertion into the ER. Thus, our data suggest
that deubiquitinases rescue post-translationally targeted membrane proteins that are
inappropriately ubiquitinated by PQC in the cytosol.
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2.3: Introduction
Membrane proteins are essential for eukaryotic life, but there are challenges
particular to the synthesis and insertion of membrane proteins (Shao and Hegde, 2011).
Membrane proteins contain hydrophobic transmembrane domains (TMDs) that typically
reside within a membrane, and are thus shielded from the aqueous cytosol. However,
nearly all membrane proteins begin their synthesis in the cytosol. This raises the problem
of exposing and aggregating hydrophobic TMDs in the aqueous cytosol during their
synthesis, damaging cellular protein homeostasis (Hegde and Zavodszky, 2019).
Evolution solved this problem by coupling protein synthesis and insertion at the
endoplasmic reticulum (ER), where the majority of membrane proteins are synthesized
(Cymer et al., 2015). These proteins typically contain either an N-terminal signal
sequence or TMD that is co-translationally recognized by the signal recognition particle
(SRP) in the cytosol (Zhang and Shan, 2014). The SRP-bound ribosome-nascent chain
complex is then delivered to the ER-localized SRP receptor, and the nascent chain is cotranslationally integrated into the membrane via the Sec61 translocon pore (Rapoport,
2007).
There are exceptions to the co-translational protein insertion pathway. Tailanchored (TA) membrane proteins are an essential class of proteins that are precluded
from SRP binding upon translation (Kutay et al., 1995; Kutay et al., 1993). TA proteins
are distinguishable by their single TMDs located at their carboxyl terminus. When the Cterminal TMD of a nascent TA protein emerges from the ribosome exit tunnel, SRP is
unable to bind and pause translation because translation has already terminated (Kutay et
al., 1995). Therefore, the nascent TA protein is released into the cytosol, and additional
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factors are needed to shield the hydrophobic TA membrane domain and deliver it to the
correct membrane. TA proteins must be distinguished from misfolded and mislocalized
proteins since protein quality control (PQC) pathways use exposed hydrophobicity as a
signal for degradation (Ciechanover and Kwon, 2017; Fredrickson et al., 2013; Xu et al.,
2016). Additionally, TA proteins must be sorted to the correct insertion pathway for
various membranes including the ER, mitochondria, and peroxisome (Borgese et al.,
2019). TA proteins play critical roles in virtually all aspects of cell biology such as
protein translocation, intracellular trafficking, and programmed cell death (Chacinska et
al., 2009; Shamas-Din et al., 2013; Sudhof and Rothman, 2009). Thus, a mechanistic
understanding of the targeting and maturation of TA proteins is of basic cell biological
and physiological significance.
Recent studies have discovered multiple pathways that mediate targeting of TA
proteins to subcellular locations, in particular to the ER (Aviram et al., 2016; Colombo et
al., 2009; Favaloro et al., 2008; Guna et al., 2018; Rabu et al., 2008; Stefanovic and
Hegde, 2007). The GET/TRC pathway (in yeast/mammals) routes TA proteins, especially
the more hydrophobic ones, to the ER for insertion (Chartron et al., 2012a; Chio et al.,
2017a; Denic et al., 2013; Hegde and Keenan, 2011). In mammals, SGTA first captures
the newly synthesized TA proteins and then hands them over to TRC40 (Shao et al.,
2017; Wang et al., 2010). The transfer reaction from SGTA to TRC40 is mediated by the
BAG6 complex, which is composed of BAG6, TRC35, and Ubl4A (Leznicki et al., 2010;
Mariappan et al., 2010; Mock et al., 2015; Shao et al., 2017). The TRC40-bound TA
proteins are then delivered to the ER-localized WRB/CAML receptor complex for
insertion (Vilardi et al., 2011; Yamamoto and Sakisaka, 2012). In vitro reconstitution
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studies have shown that the BAG6 complex can also function as a triaging factor. If
SGTA-bound TA proteins are not promptly transferred to TRC40, the BAG6 complex
captures such TA proteins and mediates their ubiquitination and subsequent degradation
(Hessa et al., 2011; Rodrigo-Brenni et al., 2014; Shao et al., 2017). This triage step has
been proposed to distinguish between TA proteins for insertion and mislocalized proteins
for degradation. However, it is still unclear how newly synthesized hydrophobic TA
proteins escape from recognition and ubiquitination by the cytosolic PQC system, which
encompasses a network of chaperones and E3 ubiquitin ligases (Ciechanover and Kwon,
2017). Here, we found that nascent TA proteins are not efficiently shielded from
recognition by PQC in the cytosol. Instead, the newly synthesized TA proteins are
ubiquitinated in cells and in vitro. Upon further investigation, we found that despite clear
ubiquitination of nascent TA proteins, few were actually degraded. In fact, ubiquitinated
TA proteins were still transferred to TRC40 and inserted, and the insertion was closely
timed with deubiquitination. The contrast between ubiquitinated TA proteins in the
cytosol and minimal ubiquitinated TA proteins at the ER membrane led to our discovery
that ER-associated deubiquitinases USP20 and USP33 deubiquitinate TA proteins at the
ER membrane. Taken together, our data suggest that nascent TA proteins are
ubiquitinated in the cytosol, whereupon they are captured and deubiquitinated both before
and after insertion into the ER membrane.

2.4: Results
2.4.1: Newly synthesized TA proteins are ubiquitinated in cells.
A hallmark of the co-translational protein insertion pathway is that protein
synthesis and insertion of TMDs are coupled at the ER membrane (Cymer et al., 2015).
23

This precludes the exposure of TMDs to the cytosol. However, numerous nascent TA
proteins that have hydrophobic C-TMDs are released into the cytosol and are posttranslationally inserted into cellular membranes. The cytosol harbors an extensive protein
quality control (PQC) network, which often recognizes exposed hydrophobicity of
misfolded or mislocalized proteins and marks them for proteasomal degradation by
adding ubiquitin chains. Therefore, we asked how cells can distinguish between
degradation and insertion substrates. We hypothesized that if TA proteins are shielded
from cytosolic PQC machinery, they should not be ubiquitinated and degraded in cells.
To test this, we constructed TA proteins that vary in the hydrophobicity of their Cterminal TMDs (Fig. 10A). First, we examined whether newly synthesized TA proteins
are ubiquitinated in the cytosol before their targeting and insertion into the ER
membrane. In vitro translation of the TA protein Sec61β, a component of the Sec61
translocon, in rabbit reticulocyte lysate (RRL) resulted in modifications consistent with
ubiquitination of Sec61β (Fig. 9A), which matches with the previous study (Hessa et al.,
2011). The ubiquitination was dependent on the TMD since its removal resulted in a
significant loss of ubiquitination.
Since nascent TA protein ubiquitination has only been observed in vitro (Hessa et
al., 2011; Shao et al., 2017), we asked whether this occurs in cultured cells. To address
this, we co-transfected HEK293 cells with HA-Ubiquitin and FLAG-tagged VAPA, an
abundant TA protein that plays a central role in mediating ER-membrane contact sites
(Murphy and Levine, 2016). The cell lysates were immunoprecipitated for VAPA using
RIPA buffer to remove most protein-protein interactions and probed for ubiquitinated
VAPA with anti-HA antibodies. Consistent with in vitro data, the immunoblotting
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analysis showed that VAPA was ubiquitin modified in a C-terminal TMD-dependent
manner in cells (Fig. 9B). The insertion of VAPA into the ER membrane was mirrored
by N-glycosylation (indicated by an orange dot) of the engineered N-glycan acceptor
motif introduced at the C-terminus of VAPA. The N-glycosylation of VAPA was verified
by its sensitivity to endoglycosidase H (Endo H) (Fig. 10B and 10C). We also detected
TA protein ubiquitination when cells were harvested in hot SDS buffer and
immunoprecipitated after dilution, which argues that TA protein ubiquitination is not a
post-lysis artifact (Fig. 10D). Also, the ubiquitination was not due to transient
overexpression of TA proteins because the ubiquitination could be detected from cells
stably expressing a TA protein (Fig. 10E).
Without a TMD, both Sec61β and VAPA are no longer ubiquitinated (Fig. 9A
and 9B). To determine that the TMD (and not the deletion mutation) is the cause of the
ubiquitination, we appended the VAMP2 TMD to the soluble protein DHFR. DHFR was
ubiquitinated similar to Sec61β and VAPA after adding a C-terminal TMD (Fig. 9C).
Therefore, the presence of a tail-anchored membrane domain can lead to ubiquitination
(Fig. 9D). However, not all TA-TMDs are equal; their hydrophobicity varies greatly
among substrates (Fig. 10A). We reasoned that more hydrophobic TA proteins may be
more attractive substrates for the cytosolic PQC machinery in cells and therefore show
stronger ubiquitin signals. To test this, we constructed fusion constructs where we
swapped the TMD of Sec61β with either VAMP2 TMD or VAMP2 hydrophobic TMD,
in which less hydrophobic amino acids were replaced with more hydrophobic amino
acids (Fig. 10A). Since they all contain the same cytosolic domain of Sec61β, these
constructs allowed us to specifically determine the role of TMD hydrophobicity in
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mediating ubiquitination. Indeed, we found that the hydrophobic VAMP2 construct
showed strong ubiquitination, even though the level of total protein was less than other
constructs. By contrast, the less hydrophobic construct Sec61β showed a moderate level
of ubiquitination (Fig. 9E and Fig. 10A).

Figure 9: TA proteins are ubiquitinated dependent on their hydrophobic TMDs

Figure 9: (A) Sec61β-encoding transcripts were translated in rabbit reticulocyte lysate
(RRL) and directly analyzed by SDS-PAGE autoradiography. (B) FLAG-tagged VAPA
or VAPA lacking its TMD was transfected along with HA-Ubiquitin into HEK293 cells.
The lysates were immunoprecipitated with anti-FLAG beads and analyzed by
immunoblotting with anti-HA for ubiquitinated substrates and anti-FLAG for VAPA. The
orange circle indicates the inserted form of VAPA that was glycosylated due to its C26

terminal glycosylation motif. (C) FLAG-tagged DHFR or DHFR fused with the VAMP2
TMD was transfected and analyzed as in B. Data representative of two independent
experiments. (D) Diagram displaying that TA proteins are ubiquitinated dependent on the
presence of their TA-TMD. (E) The indicated constructs with varying hydrophobicity of
TMDs were transfected and analyzed as in B.

Figure 10: TA TMDs, glycosylation, and expression
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Figure 10: (A) The TMD sequences of the indicated proteins are shown in blue color.
The red text denotes the glycosylation tag. The TMD hydrophobicity score was
calculated using the grand average hydropathy (GRAVY) calculator. Hydrophobic (Hy)β-VAMP2 was created by replacing less hydrophobic residues with hydrophobic amino
acids in the TMD of VAMP2. Star indicates mutations in β-VAMP2-Hy. ER-Fis1 was
created by replacing the last three amino acids of Fis1 with an N-glycosylation site. (B)
The indicated constructs were immunoprecipitated with anti-FLAG beads and boiled in
1% SDS buffer. The samples were diluted and incubated without or with endoglycosidase
H (Endo H). The samples were immunoblotted for Ub-substrates via anti-HA antibody
and TA substrates via anti-FLAG antibody. (C) Diagram showing the enzyme activity of
Endoglycosidase H removing the N-glycans from substrates. (D) Lysis buffer containing
1% SDS was heated to 95° C and added directly to the plated cells expressing β-VAMP2
and HA-Ubiquitin. The buffer was diluted down to 0.1% SDS and β-VAMP2 was
immunoprecipitated and analyzed as in B. (E) HEK293 cells stably expressing β-VAMP2
were transiently transfected with Ub-HA and lysed with RIPA. β-VAMP2 was
immunoprecipitated and analyzed as in B.

We next asked whether TA proteins are ubiquitinated in the cytosol or at the ER
membrane. To address this, we fractionated cells expressing TA proteins using a low
concentration of digitonin, which selectively permeabilized the plasma membrane but not
the ER (Fig. 11A). Even though the total amount of TA proteins in the cytosol was
minimal compared to the membrane, immunoblotting of ubiquitinated TA proteins after
immunoprecipitation revealed a strong ubiquitination signal in the cytosol fraction
compared to the membrane fraction (Fig. 11B). Newly translated TA proteins reside
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transiently in the cytosol and are rapidly inserted into the ER membrane. Therefore,
immunoblotting only detected the larger pool of TA proteins localized in the membrane
fraction, but nascent TA proteins were readily detected in the cytosol by radiolabeling, a
very sensitive technique which can detects specifically nascent TA proteins. (Fig. 11B).
These results suggest that despite the transient nature and low total yield of cytosolic TA
proteins, the majority of the ubiquitin signal comes from this population. Importantly,
glycosylated TA proteins were only detected in the membrane fraction, suggesting that
the fractionation successfully isolated the cytosolic fraction (Fig. 11B). Moreover, most
ubiquitinated TA proteins were not sensitive to Endo H, suggesting that TA protein
ubiquitination occurs in the cytosol before insertion (Fig 10B). To determine if the
ubiquitination of TA proteins is occurring immediately after their synthesis in the cytosol,
we in vitro translated the TA proteins in RRL and monitored ubiquitination at various
time points. The ubiquitination of β-VAMP2 could be detected within 10min of
translation, and more ubiquitinated β-VAMP2 appeared as the translation time further
proceeded (Fig. 11C). This result also shows that the TA ubiquitination occurs
independent of any membrane-bound ubiquitination machinery and further supports the
idea that nascent TA proteins are ubiquitinated in the cytosol before insertion into the ER.
As in the in vitro data, the ubiquitinated TA proteins could be directly detected even upon
5 min of labeling in cells, and TA protein ubiquitination continuously increased along
with translated TA proteins (Fig. 11D). Quantification of ubiquitinated VAPA revealed
that about 8% of nascent cytosolic TA proteins are ubiquitinated (Fig. 11E). Collectively,
these results suggest that a small fraction of newly synthesized TA proteins are
ubiquitinated in the cytosol before insertion into the ER membrane.
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Figure 11: Nascent TA proteins are ubiquitinated in the cytosol.

Figure 11: (A) Diagram of how .01% digitonin disrupts the
plasma membrane to release the cytosol without solubilizing
the ER allowing for separation of cytosol from membrane
fractions via centrifugation. (B) The cells transfected with the
indicated constructs and HA-Ubiquitin were metabolically
labeled and fractionated into cytosol and membrane using
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digitonin. Both cytosol and membrane fractions were immunoprecipitated with antiFLAG beads and analyzed by immunoblotting with anti-HA for ubiquitinated substrates
and anti-FLAG for TA substrate. The orange circle indicates the inserted forms that were
glycosylated due to engineered C-terminal glycosylation motifs. The immunoprecipitants
were also analyzed by autoradiography. (C) β-VAMP2-encoding transcripts were in vitro
translated in RRL for the noted times and analyzed by SDS-PAGE autoradiography
directly (Total) or after isolation of His-tagged ubiquitin-conjugated TA proteins using
Talon resin. (D) Cells expressing FLAG-VAPA were metabolically labeled for the
indicated time points and analyzed by autoradiography directly (input) or after
immunoprecipitation with anti-FLAG antibodies. Data representative of two independent
experiments. (E) Radiolabeled VAPA was immunoprecipitated via its FLAG tag and
treated with buffer, purified recombinant USP30, or USP2, and analyzed by
autoradiography. The unmodified VAPA was quantified and USP2 treated VAPA was set
as 100%.

2.4.2: TA proteins carry a K48-linked polyubiquitin chain
The distribution of ubiquitin attached to proteins may vary, as in
polyubiquitination or multi-monoubiquitination (Komander and Rape, 2012). The type of
ubiquitination modification on a protein can determine its downstream fate. We therefore
asked whether TA proteins are polyubiquitinated or multi-monoubiquitinated in cells. To
this end, we generated various lysine mutants of our model substrate β-VAMP2 and
monitored their ubiquitination in cells. Polyubiquitination of β-VAMP2 harboring a
single lysine residue was similar to β-VAMP2 containing multiple lysine residues,
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supporting the conclusion that TA proteins are polyubiquitinated in cells (Fig. 12A).
Polyubiquitination can occur on different lysine residues of ubiquitin, and lysine 48
(K48) modification mediates recognition of proteins by the proteasome. To determine the
type of polyubiquitination on TA proteins, we performed immunoblotting of
immunoprecipitated VAPA from cells using K48-ubiquitin linkage specific antibodies.
Indeed, both anti-ubiquitin and K48-linkage specific antibodies detected
polyubiquitinated VAPA on immunoblots (Fig. 12B). Next, VAPA and β-VAMP2 were
co-expressed with wildtype ubiquitin-HA, K48R mutant ubiquitin-HA, or lysine-free
mutant ubiquitin-HA. For all three ubiquitin constructs, the bottom two bands on the
αHA blot corresponding to one and two ubiquitins attached to the TA protein were
similar with each other. However, both K48R and lysine-free ubiquitin showed a
decrease in the upper bands of polyubiquitinated TA proteins (Fig 12C and 12D). These
results suggest that TA proteins are decorated with K48-linked ubiquitin chains that are
suitable for recognition by proteasomes but other ubiquitin linkages are possible and
likely present.
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Figure 12: Characterization of TA protein ubiquitination
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Figure 12: (A) β-VAMP2 with progressively more lysine residues mutated to arginine
residues were immunoprecipitated and analyzed by immunoblotting for β-VAMP2 or
ubiquitinated β-VAMP2. Data representative of two independent experiments. (B) VAPA
was immunoprecipitated and ubiquitinated VAPA was directly analyzed by
immunoblotting with either anti-ubiquitin or K48-linkage specific polyubiquitin
antibody. (C) VAPA was co-expressed with ubiquitin-HA, K48R ubiquitin-HA mutant,
or lysine-free ubiquitin-HA mutant. VAPA was immunoprecipitated from cell lysates
with αFLAG beads. αHA antibody was used in western blot analysis to examine
ubiquitinated VAPA. (D) β-VAMP2 was expressed and treated as in C.

2.4.3: TA protein ubiquitination is not due to the limitation of cytosolic
targeting factors.
We next reasoned that if TA protein ubiquitination is caused by the saturation of
targeting factors, adding purified recombinant targeting factors should suppress TA
protein ubiquitination. To test this, we in vitro translated TA proteins in RRL with
increasing concentrations of purified recombinant TRC40, the final targeting factor in the
cytosol that delivers TA proteins to the ER membrane for insertion (Fig. 13A). Adding an
excess of TRC40 did not inhibit the ubiquitination of nascent Sec61β (Fig. 13B) nor βVAMP2 (Fig. 14A), which demonstrates that TA protein ubiquitination is not due to a
limitation of the targeting factor. We further investigated this idea in cells by
overexpressing targeting factors one at a time. Transient overexpression of SGTA or
BAG6 did not appreciably influence the ubiquitination of the TA protein (Fig. 13C).
However, overexpressing TRC40 did lead to an increase in TA ubiquitination. This is
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likely due to slowed insertion, as overexpressed TRC40 may exhibit a dominant negative
effect by binding to ER insertion factors (WRB/CAML) and blocking the TRC40 loaded
with TA proteins (Fig. 13C). Since overexpressing chaperones failed to protect nascent
TA proteins from ubiquitination, we asked if one of these chaperones was actually
responsible for the ubiquitin signal we observed. Since BAG6 is known to bind to E3
ligase RNF126 (Rodrigo-Brenni et al., 2014), we hypothesized that TA proteins are
ubiquitinated via binding to a chaperone known to recruit ubiquitination machinery.
Therefore, we knocked out SGTA and BAG6 and created a partial knockout of CAML in
HEK293 cells by CRISPR/Cas9. We were unable to knock out TRC40 or completely
knock out CAML, presumably because these mutations would be lethal to cells. TA
proteins were still able to be inserted as shown by glycosylation in cells lacking SGTA or
BAG6 (Fig. 14B), implying that TRC40 and the WRB/CAML complex are sufficient for
insertion of TA proteins in cultured cells. The knockout of SGTA had little effect on TA
protein ubiquitination (Fig. 13D). To our surprise, knockout of BAG6 did not show any
appreciable defects in TA protein ubiquitination (Fig. 13D and Fig. 14C), suggesting
ER-targeted TA proteins can be ubiquitinated independently of BAG6 in cells. By
contrast, the partial knockout of CAML drastically increased TA ubiquitination compared
to control cells, likely due to the accumulation of non-targeted TA proteins in the cytosol
(Fig. 13D).
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Figure 13: Chaperone availability does not influence the ubiquitination of TA
proteins.

Figure 13: (A) Coomassie blue stained gel showing the purified recombinant TRC40
from E. coli. (B) Sec61β encoding transcripts were in vitro translated in RRL including
increasing concentrations of purified TRC40. The translated products were directly
analyzed by autoradiography. (C) HEK293 cells were transfected with the indicated
constructs along with HA-Ubiquitin. The lysates were either directly analyzed (input) or
analyzed after immunoprecipitation with anti-FLAG beads by immunoblotting for the
indicated antigens. The endogenous proteins were denoted as “end.” The orange circle
indicates the inserted and glycosylated form of VAPA. The star indicates BAG6-FLAG
which was immunoprecipitated with VAPA due to the shared tags. (D) The indicated cell
lines were transfected with FLAG-VAPA along with HA-Ubiquitin and analyzed as in C.
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Figure 14: Characterization of TA protein ubiquitination

Figure 14: (A) β-VAMP2 encoding transcripts were in vitro translated in RRL including
increasing concentrations of purified TRC40. The samples were either
immunoprecipitated for β-VAMP2 with anti-FLAG antibodies or isolated for ubiquitinconjugated TA proteins using Talon resin and analyzed by SDS-PAGE autoradiography.
(B) Wild type, SGTA-/-, or BAG6-/- cells were transfected with β-VAMP2 and
radiolabeled for 30 min and chased for 2h. β-VAMP2 was immunoprecipitated and
analyzed via SDS-PAGE autoradiography. (C) Wild type or BAG6-/- cells were
transfected with β-VAMP2. The cells were then treated with either 20µM MG132 or no
treatment for 4h. The TA protein was immunoprecipitated via its FLAG tag and analyzed
by western blotting with αHA for ubiquitinated substrates.

Previously, it was proposed that the BAG6 complex, a component of the TA
insertion pathway, functioned to triage mislocalized proteins for ubiquitination and
degradation while passing TA proteins onto TRC40 for ER insertion (Shao and Hegde,
2016; Shao et al., 2017). However, we observed clear TA ubiquitination regardless of the
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availability of chaperones. Since ubiquitination is so closely tied to misfolded proteins
and degradation, we wanted to rule out the possibility that TA proteins are ubiquitinated
because they are not properly handed over to the final targeting factor, TRC40.
Immunoprecipitation of endogenous TRC40 revealed that ubiquitinated VAPA could be
captured by TRC40 (Fig. 15A). The endogenous TRC40 selectively bound to the
ubiquitinated TA protein, but not to VAPA lacking its TMD. It is unlikely that this result
is due to a TRC40-BAG6 interaction, because TRC40 could capture ubiquitinated TA
proteins even in the absence of BAG6 in cells (Fig. 15B). If TRC40 can capture
ubiquitinated TA proteins, we should be able to detect the endogenous ubiquitinated
proteins associating with the endogenous TRC40. To evaluate this, we passed the cytosol
extract of HEK293 cells through anti-TRC40 antibody-conjugated agarose beads and
selectively eluted TRC40-associated proteins using Triton X-100 to disrupt hydrophobic
interactions between TRC40 and TA proteins. Immunoblotting of eluted samples
revealed that the endogenous TRC40 could indeed capture ubiquitinated proteins, which
were confirmed by treatment with a promiscuous deubiquitinase, USP2 (Fig. 15C). The
ubiquitinated proteins were slightly increased in CAML-depleted cells compared to WT
cells because ubiquitinated TA proteins likely accumulate in the cytosol in the absence of
CAML, which is essential for mediating TA protein insertion into the ER. Interestingly,
the endogenous VAPA could be detected in TRC40-associated proteins, which confirms
that TRC40 substrates are TA proteins (Fig. 15C). Collectively, these data suggest that
ubiquitinated TA proteins are captured by TRC40 for targeting to the ER membrane.
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Figure 15: TRC40 binds ubiquitinated TA proteins.

Figure 15: (A) HEK293 cells were transfected with empty vector, FLAG-VAPA, or
FLAG-VAPA TMD along with HA-Ubiquitin. The cells were lysed with 0.05%
digitonin so as to not disrupt the TRC40-substrate TMD hydrophobic interaction and
immunoprecipitated with anti-GFP (control) or anti-TRC40 antibodies. Data
representative of two independent experiments. (B) TRC40 was immunoprecipitated and
examined as in A with the addition of comparing wild type with BAG6-/- HEK293 cells.
(C) Endogenous cytosolic proteins from HEK293 or CAML-depleted HEK293 cells were
isolated using 0.015% digitonin, and TRC40 was purified using anti-TRC40 antibodies
conjugated to agarose. Anti-RFP antibodies conjugated to agarose served as a control.
TRC40-bound substrates were eluted via 1% Triton X-100 and treated without or with
USP2 before analyzing by immunoblotting for the indicated antigens.
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2.4.4: Deubiquitination and insertion of TA proteins are coupled at the
ER membrane.
The aforementioned data suggest that nascent TA proteins are ubiquitinated in the
cytosol regardless of relevant chaperone availability. We reasoned that if ubiquitinated
TA proteins are destined for degradation, our model TA substrates should exhibit reduced
half-lives. In contrast, pulse-chase experiments revealed that our model TA proteins, VAMP2 and VAPA, were very stable up to 8h of chase (Fig. 16A). β-VAMP2 was
immunoprecipitated after cycloheximide treatment to block protein translation. The
ubiquitination signal was lost after cycloheximide and was not recovered with the
addition of the proteasome inhibitor MG132 (Fig. 16B). This suggests that ubiquitinated
TA proteins are recently translated and are deubiquitinated but not degraded. To further
determine the fate of ubiquitinated TA proteins, we compared VAPA with a model
misfolded protein XBP1(L246A) mutant (XBP1m). Spliced XBP1 (X-box binding
protein 1) is a transcription factor that increases ER capacity and ER-associated
degradation (Acosta-Alvear et al., 2018). XBP1 is normally targeted to the ER membrane
by the SRP pathway (Kanda et al., 2016; Plumb et al., 2015), but a mutation (L246A) in
the translational pausing sequence impairs targeting to the ER, thus leading to release
from the ribosome into the cytosol and mislocalization (Yanagitani et al., 2011). The
XBP1m is then ubiquitinated and degraded. We compared VAPA with XBP1m using a
cycloheximide (CHX) chase combined with a ubiquitination assay. The ubiquitinated
population of VAPA gradually decreased during the CHX chase period without a
significant loss of the total VAPA proteins. The ubiquitinated VAPA was not destined for
degradation since cells treated with both CHX plus MG132 did not significantly stabilize
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ubiquitinated proteins (Fig. 16C). By contrast, the ubiquitinated XBP1m was decreased
during the CHX chase with the concomitant loss of total proteins. Both ubiquitinated and
total proteins of XBP1m were accumulated upon inhibiting the proteasome. This result
suggests that VAPA exhibits features different from a typical misfolded protein despite
having similar levels of ubiquitination (Fig. 16C). Similarly, we observed that -VAMP2
was gradually deubiquitinated upon inhibiting protein synthesis by CHX without a
significant loss of the total -VAMP2 proteins (Fig. 16D). Interestingly, the
deubiquitination of monoubiquitinated and glycosylated -VAMP2 was significantly
slower than that of polyubiquitinated species (Fig. 16D). This result also suggests that
monoubiquitinated TA proteins can be inserted and glycosylated, whereas
polyubiquitinated proteins are deubiquitinated before insertion into the ER membrane.
We next asked whether complete deubiquitination of TA proteins can occur
before their insertion into the ER membrane. To address this, we constructed a VAMP2-CKK construct where all lysine residues in the cytosolic domain were replaced
with arginine residues, leaving two lysine residues in the C-terminus after the TMD. We
speculated that -VAMP2-CKK must be fully deubiquitinated before insertion as the
ubiquitination of C-terminal lysine residues would hinder the insertion of the TMD.
Indeed, we detected very little monoubiquitinated and glycosylated -VAMP2-CKK
compared to -VAMP2 (Fig. 17A). The monoubiquitinated and glycosylated band was
sensitive to Endo H digestion, confirming that this population was inserted with
monoubiquitination. These results support the conclusion that deubiquitination of TA
proteins can occur either before or after insertion into the ER membrane.
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We next asked whether TA protein ubiquitination in the cytosol is coupled with
deubiquitination at the ER membrane. To test this, we monitored the newly synthesized
TA proteins by chasing metabolically-labeled cells expressing VAPA. The cells were
fractionated at each time point to separate the cytosol from the membrane fraction.
Immunoprecipitation of VAPA revealed a clear ubiquitination signal from VAPA in the
cytosol at the zero-time point (Fig. 17B). The ubiquitinated VAPA in the cytosol fraction
gradually disappeared during the chase period with a concomitant increase in the signal
of inserted and glycosylated VAPA in the membrane fraction. We noticed that although
VAPA was inserted efficiently into the ER, as shown by its efficient membrane
localization at 4h (Fig. 17B), VAPA was not fully glycosylated, likely due to a shorter Cterminal glycosylation motif compared to -VAMP2 (Fig. 10A). To further determine if
TA protein deubiquitination occurs in vitro, we translated -VAMP2 and stopped protein
synthesis by removing ribosomes by centrifugation. The post-translation incubation of
ubiquitinated VAMP2 with crude rough microsomes prepared from HEK293 cells led to
its insertion as shown by glycosylation with a concomitant reduction in ubiquitinated
species (Fig. 17C). Ubiquitinated TA proteins are not degraded by the proteasome, but
could autophagy be eliminating the ubiquitinated TAs? Bafilomycin disrupts autophagy
by blocking the fusion of autophagosomes with lysosomes (Redmann et al., 2017).
Combination treatment of bafilomycin and MG132 blocks both the proteasome and
autophagy, but the loss of TA ubiquitin signal was unaffected (Fig. 17D). Collectively,
our results suggest that nascent TA proteins are ubiquitinated in the cytosol and yet are
still routed to the ER membrane for deubiquitination and insertion.
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Figure 16: Ubiquitinated TA proteins are deubiquitinated and inserted into ER
membrane.

Figure 16: (A) FLAG-tagged β-VAMP2- or VAPA-expressing cells were metabolically
labeled and chased for the indicated time points. The cell lysates were
immunoprecipitated with anti-FLAG beads and analyzed by SDS-PAGE
autoradiography. The protein level at 0h time point was taken as 100%, and the
percentage of the remaining protein was calculated with respect to 0h. The orange circle
indicates the glycosylated forms of TA proteins. (B) Cells expressing β-VAMP2 and
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ubiquitin-HA were directly harvested or treated with MG132, cycloheximide, or a
combination of MG132 and cycloheximide and then harvested. β-VAMP2 was
immunoprecipitated and ubiquitinated β-VAMP2 was analyzed via western blotting for
αHA. (C) VAPA or a degradation model substrate, XBP1u mutant (L246A), was
expressed in HEK293 cells. Cells were treated with cycloheximide (CHX) alone or with
proteasome inhibitor MG132 for the indicated durations. VAPA and XBP1m were
immunoprecipitated via anti-FLAG antibody beads and analyzed by immunoblotting with
anti-FLAG for substrates and anti-HA antibody for ubiquitinated substrates. Data
representative of two independent experiments. (D) FLAG-tagged β-VAMP2- and HAUbiquitin-expressing cells were treated and analyzed as in C. Note that the
monoubiquitinated and glycosylated form of VAMP2 (Ub1-Gly) could be detected,
suggesting that deubiquitinases do not efficiently remove all ubiquitin chains before TA
protein insertion.
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Figure 17: TA proteins are deubiquitinated at the ER.

Figure 17: (A) FLAG-β-VAMP2 or β-VAMP2 C-ter. KK mutant (all lysine residues in
the cytosolic domain were replaced with arginine residues, leaving two lysine residues in
the C-terminal tail) was transfected along with HA-Ubiquitin and immunoprecipitated
with anti-FLAG beads and analyzed as in by western blotting after treating the samples
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with or without Endo H. (B) FLAG-VAPA-expressing cells were metabolically labeled
and chased for the indicated time points. At each time point, cells were permeabilized
with digitonin to collect cytosol and membrane fractions. The samples were
immunoprecipitated with anti-FLAG beads and analyzed by autoradiography. (C) βVAMP2 was translated in RRL and centrifuged to remove ribosomes. The supernatant
was incubated with either buffer or crude rough microsomes derived from HEK293 cells.
The samples were analyzed by autoradiography after immunoprecipitating with antiFLAG beads or isolation of His-tagged ubiquitin-conjugated β-VAMP2 using Talon
resin. (D) Cells expressing VAPA and ubiquitin-HA were not treated, treated with
MG132, or treated with MG132 and bafilomycin. Then VAPA was immunoprecipitated
and ubiquitinated VAPA was analyzed via western blotting with αHA.

2.4.5: USP19 is not responsible for TA deubiquitination, but can
compete for insertion.
Nascent ubiquitinated TA proteins are not being degraded and instead are being
properly routed for ER insertion and deubiquitination. Furthermore, minimal TA
ubiquitination was detected in membrane fractions (Fig. 11B). Therefore, I hypothesized
that a deubiquitinase (DUB) must reside near or at the ER membrane to act on
ubiquitinated TA proteins. USP19 is a DUB anchored to the ER by a TMD. USP19 has
previously been shown to deubiquitinate both ER membrane proteins such as HRD1 and
cytosolic misfolded proteins (Harada et al., 2016; Hassink et al., 2009; Xu et al., 2018).
Since USP19 functions at the ER, we hypothesized that it may be the DUB responsible
for removing ubiquitin from incoming nascent TA proteins.
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To determine if USP19 acts on nascent TA proteins, I co-expressed β-VAMP2
and a deubiquitinase USP19 and immunoprecipitated β-VAMP2. USP19 overexpression
successfully removed ubiquitin from TA proteins (Fig. 18A). However, a loss of
insertion efficiency also occurred when USP19 is over-expressed as shown by the
increase in the non-glycosylated band of β-VAMP2. Furthermore, this loss of insertion
efficiency is less impactful on the β-VAMP2 lysine-free mutant suggesting a link
between TA protein ubiquitination and insertion. The deubiquitination and impairment of
insertion also affects VAPA when USP19 is over-expressed (Fig. 18A and 18B). Since
exogenous USP19 can deubiquitinate TA proteins, I next asked if endogenous USP19 is
the DUB responsible for the nascent TA proteins. This is an important distinction because
overexpressing a DUB may allow it to act on substrates that it normally would not
interact with under basal expression. Therefore, I created a USP19 CRISPR/Cas9
knockout HEK cell line. If USP19 is the DUB acting on TA proteins, then TA proteins
should exhibit increased ubiquitination in USP19 KO cells. I purified VAPA from
cytosol or membrane fractions of WT or USP19 KO cells and found that neither
ubiquitination or insertion were affected by the loss of USP19 (Fig. 18C). I repeated this,
but with total cell lysis instead of fractionation and again found no change in VAPA
ubiquitination or insertion (Fig. 18D).
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Figure 18: USP19 is not required for TA protein deubiquitination.

Figure 18: (A) HEK293 cells were transfected with the labeled TA proteins and either
vector or USP19. The TA proteins were immunoprecipitated via their FLAG-tags and
analyzed via western blotting for either αFLAG for the TA protein or αHA for ubiquitin.
The orange circle denotes the glycosylated form of the TA proteins. (B) VAPA was
examined as in A to show reproducibility of this result. (C) WT or USP19 KO Cells
expressing VAPA were radiolabeled and chased for the indicated time points. The cells
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were then fractionated into cytosol and membrane fraction via the detergent digitonin to
permeabilize the cell membrane and centrifugation to separate membranes from the
release cytosol. VAPA was immunoprecipitated and examined via gel electrophoresis
followed by developing autoradiography film. (D) VAPA was examined as in C, but with
total lysates instead of fractionation.

Although USP19 does not appear to be required for TA deubiquitination, the loss
of TA protein insertion efficiency raised new questions. Could premature
deubiquitination by the overexpressed DUB somehow impair TA protein insertion? To
determine if the loss of insertion was due to the catalytic deubiquitinase activity of
USP19, I co-expressed β-VAMP2 with either wildtype USP19 or USP19 catalytically
inactive mutant. After quantifying the percent of β-VAMP2 that was glycosylated and
inserted, I found that both wildtype and inactive mutant USP19 inhibited TA insertion
(Fig. 19A and 19B). USP19 is itself a TA protein, and its catalytic activity was not
blocking TA insertion, so I reasoned that its TMD could be competing with my model
substrate for insertion machinery binding. I deleted different regions of USP19 to
determine which domain impacts TA protein insertion. USP19’s ubiquitin specific
protease (USP) domain makes up the majority of the protein and is the functional domain
for deubiquitination. USP19ΔTMD did not impair TA insertion while the USP19ΔUSP
did (19C). Thus, USP19 and other TA proteins likely compete for binding to insertion
machinery when co-expressed, slowing overall TA insertion.
However, this hypothesis does not explain why β-VAMP2 lysine free mutant was
less impacted than the ubiquitinated β-VAMP2 (Fig. 18A). I verified this phenotype by
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radiolabeling β-VAMP2 versus β-VAMP2 lysine-free mutant. Again, the lysine-free
mutant was able to insert more efficiently than β-VAMP2 in the presence of USP19 (Fig.
19D and 19E). However, additional experiments are needed to quantify if the difference
between β-VAMP2 and the lysine-free mutant is significant. Could ubiquitination affect
how TAs are recognized and handled by insertion machinery thus resulting in different
competition kinetics when comparing a TA protein with its lysine-free counterpart?
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Figure 19: USP19’s TMD competes for TA protein insertion.

Figure 19: (A) β-VAMP2 was co-expressed with either vector or USP19 in HEK293
cells. The cells were radiolabeled and directly harvested. β-VAMP2 was
immunoprecipitated and examined via autoradiography. (B) Bar graph showing the
quantification of A. (C) β-VAMP2 was co-expressed with the indicated USP19 construct
or the DUB EBV. β-VAMP2 was immunoprecipitated and examined by immunoblotting
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for αFLAG. (D) β-VAMP2 or β-VAMP2ΔK were treated and examined as in A. (E)
Results from D were quantified and graphed.

2.4.6: ER-localized USP20 and USP33 deubiquitinate ER-targeted TA
proteins.
We next continued the search for the DUB that deubiquitinates TA proteins at the
ER membrane. Though most polyubiquitin chains are removed from TA proteins prior to
insertion as evidenced by the lack of simultaneously glycosylated and ubiquitinated TA
proteins (Fig. 11B), we hypothesized that an ER-localized deubiquitinase would be
ideally positioned to target any ubiquitin still attached once a TA protein reaches the ER.
We therefore focused on three deubiquitinases - USP19, USP20, and USP33 - that are
known to associate with the ER membrane (Curcio-Morelli et al., 2003; Hassink et al.,
2009; Thorne et al., 2011). To test if any of these ER-localized deubiquitinases are
involved in the deubiquitination of TA proteins, we generated CRISPR/Cas9-mediated
HEK293 knockout cells of USP19, USP20, USP33, or a mitochondria-localized USP30
as a control (Fig. 20A). Since USP20 and USP33 are homologous deubiquitinases, we
generated knockout cells depleted of both proteins as well. None of these DUBs affected
the deubiquitination of VAPA when they were individually depleted in cells. By contrast,
double knockout of homologous proteins USP20 and USP33 resulted in a significant
accumulation of ubiquitinated VAPA compared to either WT or single knockout cells
(Fig. 20A). We note that, although minimal, USP20 is still detectable in the USP20-/lanes possibly from either a small number of WT cells remaining after picking KO clones
or from spill-over from the samples from the flanking the USP20-/- lanes (Fig. 20A).
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Consistent with the previous studies (Thorne et al., 2011), we noticed that the depletion
of USP20 increased the expression level of USP33 (Fig. 20A), suggesting that these
proteins play redundant functions in cells. Unlike USP19, which is anchored to the ER
membrane via the C-terminal TMD (Hassink et al., 2009; Lee et al., 2014), USP20 and
USP33 lack predictable TMDs. We therefore tested their membrane localization by
cellular fractionation and immunoblotting. Both USP20 and USP33 are localized to the
membrane fraction of semipermeabilized cells (Fig. 20B). Additionally, immunoblotting
of ER-derived microsomes revealed that USP20 and USP33 are localized at the ER
membrane (Fig. 20C). We further verified the ER localization of USP20 and USP33 via
confocal microscopy. Endogenous USP33 co-localized with an ER protein calreticulin
(Fig. 21A). Consistent with our western blot analysis, USP33 signal was elevated in
USP20-/- cells compared to WT cells, whereas little to no signal was observed in USP33/- cells (Fig. 21A). However, endogenous USP20 was less readily detectable (Fig. 22).
We therefore overexpressed USP20 and USP33 along with the ER control PDI to verify
their localization. Both USP20 and USP33 showed colocalization with PDI (Fig. 21B).
Intriguingly, we observed the accumulation of ubiquitinated as well as
glycosylated VAPA species in USP20/33-/- cells, which were confirmed by digestion
with Endo H (Fig. 23A). This result is consistent with our hypothesis that the ERlocalized USP20/33 mediate deubiquitination after TA protein insertion and
glycosylation in the ER membrane. Cellular fractionation further revealed that
ubiquitinated VAPA was accumulated mostly in the membrane fraction of USP20/33-/cells compared to WT cells, whereas the level of cytosolic VAPA ubiquitination was
similar in both WT and USP20/33-/- cells (Fig. 23B and Fig. 25A). Interestingly, we
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only observed the accumulation of mono-, di-, and tri-ubiquitinated species, but
polyubiquitinated species were not significantly accumulated in the ER membrane of
USP20/33-/- cells compared to WT cells (Fig. 23B and Fig. 25A). These results suggest
that polyubiquitin chains are removed from TA proteins by a different deubiquitinase
before insertion into the ER membrane.
Screening of TA substrates revealed that ubiquitinated species of mini-Otoferlin,
VAMP2, and Cb5 accumulate in USP20/33-/- cells, while mitochondria-localized Fis1
was unaffected (Fig. 24A). We next wondered if artificially directing Fis1 to the ER
membrane would force its deubiquitination to be dependent on USP20/33. To examine
this, we constructed an ER-targeted Fis1 (ER-Fis1) in which the C-terminal tail is
replaced with an N-glycosylation site (Fig. 10A). Indeed, ubiquitinated as well as
glycosylated ER-Fis1 was accumulated in USP20/33-/- cells relative to WT cells (Fig.
24A), suggesting that the localization at the ER membrane is crucial for deubiquitination
of TA proteins by USP20/33. Furthermore, we asked if the depletion of USP20/30 leads
to the accumulation of endogenous ubiquitinated TA proteins. To test this, we isolated
endogenous total ubiquitinated proteins from the total lysate of WT or USP20/33-/- cells
using TUBEs (Tandem-repeated Ubiquitin-Binding Entities)-agarose. Immunoblotting
with a ubiquitin antibody confirmed that TUBEs efficiently pulled down endogenous
ubiquitinated proteins (Fig. 24B). Importantly, we were able to detect endogenous
ubiquitinated VAPA in WT cells and that the ubiquitinated VAPA accumulated more in
USP20/33-/- cells (Fig. 24B). Consistent with the results observed with our recombinant
VAPA, USP20/33-/- showed the accumulation of mono- to tri-ubiquitinated endogenous
VAPA, which could be removed by USP2 (Fig. 24B and 24C). We also noticed that
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unmodified VAPA was pulled down by TUBEs. This is presumably caused by an
interaction between ubiquitinated and non-ubiquitinated VAPA. The cycloheximide and
pulse chase experiments revealed that the accumulated TA proteins with ubiquitin
modifications in USP20/33-/- cells are not routed for proteasomal degradation (Fig. 25A
and 25B). However, the ubiquitinated XBP1m was degraded by proteasomes both in WT
and USP20/33-/- cells (Fig. 25B). Furthermore, we found no significant difference in the
insertion of TA proteins between WT and USP20/33-/- cells (Fig. 25C). Taken together,
these results suggest that USP20/33 are responsible for the deubiquitination of TA
proteins after their insertion into the ER membrane.
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Figure 20: The ER-localized USP20 and USP33 are required for deubiquitination of
TA proteins.

Figure 20: (A) HEK293 cells with the indicated CRISPR/Cas9 knockout cell lines were
transfected with VAPA-FLAG and HA-Ubiquitin. VAPA was immunoprecipitated and
immunoblotted with anti-FLAG antibody for VAPA and anti-HA antibody for
ubiquitinated VAPA. The orange circle indicates the glycosylated form of VAPA. (B)
Wild type (WT) HEK293 and USP20/33-/- cells were fractionated into cytosol and
membrane using 0.015% digitonin. Immunoblotting of TRAPα (membrane control) and
SGTA (cytosolic control) shows the successful separation of the cytosol and membrane.
Data representative of two independent experiments. (C) Increasing amounts of rough
microsomes isolated from HEK293 cells were immunoblotted for USP20, USP33, and
the membrane protein Sec61α as a control.
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Figure 21: Co-localization of USP33 and USP20 with ER markers
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Figure 21: (A) WT, USP20-/-, and USP33-/- HEK293 cells were stained for the
indicated endogenous proteins. Confocal imaging shows colocalization signal (yellow) of
USP33 (red) and Calreticulin (green). Scale bar, 10 µm. Data representative of two
independent experiments. (B) HeLa cells were transfected with the ER control protein
PDI and either USP20 or USP33 and then treated as in C for confocal microscopy. Scale
bar, 10 µm.

Figure 22: Endogenous USP20 localization

Figure 22: Either WT or USP20-/- HEK293 cells were fixed with 3.7% formaldehyde
and permeabilized in 0.1% Triton X-100. The cells were stained with Rabbit α-USP20
and Mouse α-PDI followed by Goat α-Rabbit IgG-Cy2 and Goat α-Mouse IgG-Cy3. The
stained cells were examined for colocalization (yellow) of USP20 (red) and PDI (green)
by confocal microscopy. Scale bar, 10 µm.
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Figure 23: Ubiquitinated VAPA accumulates in USP20/33-/- cells.

Figure 23: (A) VAPA-FLAG and HA-Ubiquitin were transfected into WT or USP20/33/- HEK 293 cells. VAPA was immunoprecipitated and treated without or with Endo H for
6 hours at 37°C. Samples were immunoblotted with anti-FLAG antibody for VAPA and
anti-HA antibody for ubiquitinated VAPA. The orange circle indicates the glycosylated
form of VAPA, and the bands lost in the Endo H treated sample, indicated by the star,
represent ubiquitinated and glycosylated VAPA. (B) Wild type (WT) HEK293 and
USP20/33-/- cells were fractionated into cytosol and membrane using 0.015% digitonin
as in 5A and analyzed by immunoblotting as in A. Note that nascent ubiquitinated TA
proteins were hardly detected in the cytosol fraction by immunoblotting due to their low
abundance, but they could be readily detected after metabolic labeling as shown in Figure
11B.

59

Figure 24: Ubiquitinated TA proteins accumulate in USP20/33-/- cells.
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Figure 24: (A) Cells expressing the indicated substrates along with HA-Ubiquitin were
examined as in 21A. (B) WT and USP20/33-/- cells were lysed with 1% Triton X-100
and endogenous ubiquitinated proteins were pulled down using TUBEs agarose and
analyzed by immunoblotting with anti-ubiquitin and anti-VAPA antibodies. # denotes an
unknown band. (C) Samples were obtained from USP20/33-/- cells as in B and then
TUBEs-agarose bound endogenous ubiquitinated proteins were treated without or with
USP2 before analyzing by immunoblotting. # denotes unknown bands. Star indicates
ubiquitin monomers.
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Figure 25: Ubiquitinated TA proteins accumulate in cells lacking USP20/33.

Figure 25: (A) Cells were transfected with VAPA-FLAG and HA-Ubiquitin,
radiolabeled, and chased for the indicated times. Cells were then fractionated into cytosol
and membrane with 0.015% digitonin. VAPA was then immunoprecipitated from the
membrane fraction of WT and USP20/33-/- cells and analyzed by autoradiography. Star
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represents ubiquitinated and glycosylated VAPA. The orange circle indicates the
glycosylated forms of TA proteins. (B) WT or USP20/33-/- cells expressing VAPA or
XBP1m were treated with cycloheximide (CHX) alone or with proteasome inhibitor
MG132 for the indicated durations. VAPA and XBP1m were immunoprecipitated
via anti-FLAG antibody beads and analyzed by immunoblotting with anti-FLAG for
substrates and anti-HA antibody for ubiquitinated substrates. (C) FLAG-tagged VAPAexpressing cells were metabolically labeled and chased for the indicated time points. The
cell lysates were immunoprecipitated with anti-FLAG beads and analyzed by SDS-PAGE
autoradiography. The protein level at 0h time point was taken as 100%, and the
percentage of the remaining protein was calculated with respect to 0h. The percentage of
glycosylated band from total was quantified using Image J and shown under the
autoradiography.

2.4.7: USP20 and USP33 play redundant roles in the deubiquitination of
TA proteins
To determine whether both USP33 and USP20 are required for removing
ubiquitin chains from TA proteins or if they play redundant roles, we complemented
either USP33 or USP20 into USP20/33-/- cells and monitored the deubiquitination of
VAPA by immunoblotting. Indeed, the complementation of either WT USP20 or USP33
completely deubiquitinated VAPA, supporting that either one is sufficient to remove
ubiquitin chains from TA proteins (Fig. 26A). We next asked if the catalytic activity of
USP20 or USP33 is required for the deubiquitination of TA proteins. To address this, we
generated catalytically inactive mutant versions of USP20 (C154S/H643Q) and USP33
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(C194S/H665Q) as characterized by previous studies (Berthouze et al., 2009).
Complementation with catalytically deficient mutants significantly increased the
accumulation of ubiquitinated VAPA compared to cells expressing their wild type
counterparts (Fig. 26A). Therefore, the catalytic activity of USP20 or USP33 is essential
for the deubiquitination of TA proteins. Interestingly, the expression of catalytically
inactive mutants of USP20 and USP33 further increased the accumulation of
ubiquitinated VAPA, suggesting that these mutants protect the ubiquitinated VAPA from
other deubiquitinases. Lastly, we wanted to determine if USP20 or USP33 is sufficient to
remove ubiquitin chains from TA proteins. We therefore purified Strep-tagged USP20 or
its catalytically inactive mutant (CH/SQ) from HEK293 cells (Fig. 26B). We then
immunoprecipitated radiolabeled nascent VAPA from the cytosol fraction of HEK293
cells expressing FLAG-tagged VAPA. The incubation of ubiquitinated VAPA with
purified USP20 led to complete deubiquitination of VAPA, whereas the catalytically
inactive USP20 mutant was not able to remove ubiquitin chains from VAPA (Fig. 26C)
Overall, these results establish that USP20 or USP33 directly removes the ubiquitin
chains of TA proteins at the ER membrane.
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Figure 26: The catalytic activity of USP20 or USP33 is required for the
deubiquitination of TA proteins.

Figure 26: (A) USP20, catalytically inactive USP20 mutant (C154S and H643Q),
USP33, or catalytically inactive USP33 mutant (C194S and H665Q) was transfected
along with VAPA-FLAG and HA-Ubiquitin. VAPA was immunoprecipitated via its
FLAG tag and analyzed for ubiquitination levels by immunoblotting. The orange circle
indicates the glycosylated form of VAPA. (B) A Coomassie-stained gel showing purified
USP20 and USP20 mutant from HEK293 cells transiently overexpressing Strep-tagged
versions of USP20. Non-transfected HEK293 cells were purified similarly and taken as a
mock. (C) Radio-labeled VAPA was immunoprecipitated from the cytosol fraction of
HEK293 cells expressing VAPA. The immunoprecipitated VAPA was treated with
increasing amounts of purified USP20 or catalytically inactive USP20 mutant from B and
analyzed by autoradiography. Data representative of two independent experiments.
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2.5: Discussion
TA proteins are a vital class of membrane proteins that are post-translationally
targeted and inserted into cellular membranes (Borgese et al., 2019). Due to TA proteins’
single C-terminal hydrophobic TMDs, a critical challenge for them is to evade the
cytosolic PQC, which normally recognizes exposed hydrophobicity (Ciechanover and
Kwon, 2017; Fredrickson et al., 2013; Xu et al., 2016). In this study, we find that newly
synthesized TA proteins are ubiquitinated in the cytosol. In contrast to the previously
proposed model, the ubiquitinated TA proteins are not destined for proteasomal
degradation, but rather they are properly targeted, inserted, and deubiquitinated at the ER
membrane. The ER-localized deubiquitinases USP20 and USP33 deubiquitinate TA
proteins at the ER membrane (Fig. 27).
Both our in vitro and in vivo studies show that newly synthesized TA proteins are
ubiquitinated in the cytosol. Our observation of TA protein ubiquitination is consistent
with the previous in vitro studies (Hessa et al., 2011; Shao et al., 2017). It was previously
proposed that TA protein ubiquitination was due to the limitation of targeting chaperones
in the cytosol. However, our in vitro and in vivo studies argue against this notion.
Instead, TA proteins are ubiquitinated 4regardless of chaperone availability. Surprisingly,
our data also suggest that ER-targeted TA proteins are ubiquitinated even in the absence
of BAG6 in cells. This result suggests that TA proteins are ubiquitinated upstream of
BAG6, likely as soon as their hydrophobic TMD is exposed to the cytosol after release
from ribosomes. Our observation of BAG6-independent ubiquitination resembles the
previous studies wherein BAG6 captures newly synthesized ubiquitinated proteins
(Minami et al., 2010; Yau et al., 2017). However, we cannot rule out the possibility that
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another compensatory ubiquitination machinery is induced in BAG6-/- cells. An
alternative possibility is that TA proteins are ubiquitinated twice: first after releasing
from ribosomes and second by the BAG6 complex. This may explain why the knockout
of BAG6 did not significantly reduce the ubiquitination of TA proteins. Our data also do
not rule out the ubiquitination of TA proteins occurring after binding to TRC40.
However, this seems unlikely since TA substrate binding to TRC40 has been shown to be
a commitment to ER targeting (Shao et al., 2017).
Previous in vitro reconstitution studies suggested that BAG6 functions as a
triaging factor that either channels TA proteins to the targeting factor TRC40 for
insertion or mediates ubiquitination of TA proteins for degradation when targeting fails
(Shao et al., 2017). Several lines of our evidence suggest that ubiquitinated TA proteins
are not destined for proteasomal degradation. First, ubiquitinated TA proteins are not
accumulated in cells upon inhibiting the proteasome. Instead, they are deubiquitinated
with almost no loss of total TA proteins. Second, ubiquitinated TA proteins can be passed
off to the endogenous TRC40 and inserted normally. Third, the deubiquitination of TA
proteins is closely coupled with insertion at the ER membrane. Therefore, we propose
that despite being polyubiquitinated in the cytosol, TA proteins are properly targeted and
inserted into membranes and deubiquitinated during this process.
Given that the ER membrane localized TA proteins had little ubiquitin
modification, we hypothesized that an ER-associated deubiquitinases may deubiquitinate
TA proteins after insertion. Our CRISPR-Cas9 genetic screen of known ER-associated
deubiquitinases revealed that the depletion of USP20 and USP33 results in the
accumulation of mono- to tri-ubiquitinated and glycosylated TA proteins in the
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membrane with little effect on the cytosolic polyubiquitinated TA proteins. This suggests
that USP20/33 mainly act on ubiquitinated TA proteins after their insertion into the ER
membrane, while other unidentified deubiquitinases may remove the larger polyubiquitin
chains from TA proteins prior to insertion. Additionally, our complementation
experiment suggests that homologous USP20 and USP33 play redundant roles in
removing ubiquitin chains from TA proteins. The precise mechanism by which USP20
and USP33 associate with the ER membrane remains to be investigated since they lack
TMDs, although, previous studies have identified an amphipathic region that appears to
be necessary for the ER membrane localization of USP33 (Thorne et al., 2011).
Surprisingly, we found that the ER-localized transmembrane deubiquitinase
USP19 is dispensable for deubiquitination of ER-targeted TA proteins despite the fact it
can remove K48 linked ubiquitin chains (Lee et al., 2014). We speculate that the
peripheral membrane association of USP20/33 may provide a unique advantage to access
ubiquitin chains of TA proteins compared to USP19, which is anchored to the ER
membrane via the C-terminal TMD. Since TA ubiquitination is dependent on the TMD,
ubiquitination machinery targets lysine residues located proximal to the TMD (RodrigoBrenni et al., 2014). USP20/33 may be peripherally positioned to access the ubiquitin
chains of TA proteins that are close to the lipid bilayer. This model is consistent with the
recent findings that USP20 can remove ubiquitin chains from a lysine residue of HMGCoA reductase that is located close to the lipid bilayer (Lu et al., 2020). Since USP20/33
removes ubiquitin chains of TA proteins that utilize either the TRC40 or EMC pathway
for insertion into the ER membrane (Guna et al., 2018), deubiquitination of TA proteins
by USP20/33 may not be directly coupled with insertion. We envision that USP20 and
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USP33 may also function as general ER surveillance factors to remove ubiquitin chains
from membrane proteins that are promiscuously ubiquitinated by ER-bound E3 ligases
(Zhang et al., 2013), thus rescuing functional membrane proteins from ERAD.
It is unclear why ubiquitinated TA proteins that accumulate in USP20/33-depleted
cells are not routed for proteasomal degradation. One explanation for this observation is
that these TA proteins consist of mono-, di- and tri-ubiquitinated species that are likely
not suitable for the p97 ATPase-mediated extraction from the ER membrane for
degradation by cytosolic proteasomes (Bodnar and Rapoport, 2017). However, we predict
that these modifications could inhibit the function of a TA protein by occluding
interaction with partner proteins. We find that USP20/33-mediated removal of ubiquitin
chains from TA proteins is not a prerequisite for insertion into the ER membrane.
However, future studies using various TA proteins including ones containing lysine
residues succeeding the C-terminal TMD are needed to determine if deubiquitination is
required for the insertion of select TA substrates. Our results suggest that USP20/33 are
not absolutely essential for deubiquitinating TA proteins, as deubiquitination is reduced
but not completely blocked in USP20/33-/- cells. This observation implies that other
cytosolic or ER-associated deubiquitinases can partially compensate for the role carried
out by USP20/33. Thus, USP19 may work in concert with USP20 and 33, but two
attempts to create a triple USP19/20/33 KO proved to be lethal to cells.
Our quantification result suggests that only a small fraction (8%) of the cytosolic
nascent TA protein is ubiquitinated in the cytosol fraction. However, we predict that this
number is an underestimate because ubiquitin modifications on TA proteins may survive
only a short period as they are counteracted by cytosolic deubiquitinases. This notion is
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supported by our observation that the mislocalized XBP1m, which carries similar levels
of ubiquitination as VAPA, is rapidly recognized for proteasomal degradation. We
speculate that TA proteins are not accidentally ubiquitinated by the cytosolic PQC and
that the ubiquitination may play important roles in the biogenesis of TA proteins. One
intriguing function for TA protein ubiquitination could be the suppression of TA protein
activity until it reaches the target destination in the cell. This may be particularly
important for TA proteins that interact with proteins from other cellular membranes.
We have shown that ER-targeted TA proteins are ubiquitinated in the cytosol and
subsequently deubiquitinated and inserted. We propose that such ubiquitination of
nascent membrane proteins and subsequent deubiquitination at the target membrane may
be common for all post-translationally inserted membrane proteins. Whether targeted to
the mitochondria, peroxisomes, or lipid droplets, post-translationally inserted membrane
proteins face similar challenges in traversing the aqueous cytosol with their hydrophobic
domains. This idea is consistent with the recent findings that USP30 deubiquitinates
mitochondrial proteins that are imported through the TOM complex (Ordureau et al.,
2020; Phu et al., 2020). However, it remains to be determined if USP30 can
deubiquitinate mitochondrial-targeted TA proteins.
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Figure 27: Model of nascent TA protein ubiquitination and deubiquitination

Figure 27: A fraction of newly synthesized TA proteins is polyubiquitinated in the
cytosol. The polyubiquitinated TA proteins are captured by TRC40, likely with the help
of SGTA and the BAG6 complex. The polyubiquitinated TA proteins are partially
deubiquitinated by an unknown cytosolic deubiquitinase (DUB) before insertion into the
ER membrane. The ER membrane-associated USP20 and USP33 deubiquitinate the
remaining one to three ubiquitin modifications on TA proteins.
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Chapter 3: The function of ubiquitination of nascent
TA proteins
Chapter 2 consists of my published work that shows the ubiquitination and
deubiquitination of nascent tail-anchored membrane (TA) proteins. This ubiquitination is
dependent on the transmembrane domain (TMD) of the TA protein. Instead of being
degraded, TA proteins are deubiquitinated and inserted properly into the ER membrane.
However, the discovery of ubiquitination on nascent TA proteins raises new questions.
Could the ubiquitination of TA proteins serve a functional purpose? Perhaps
ubiquitination could impact TA protein folding or protein-protein interactions.
Furthermore, many chaperones recognize and bind ubiquitinated proteins, so could TA
protein ubiquitination impact which chaperones associate with the TA protein insertion
pathway? Finally, are there undiscovered factors that function in the synthesis of TA
proteins related to this ubiquitination? I hypothesize that ubiquitination of TAs may be a
double-edge sword: simultaneously attracting protein-quality-control factors while also
shielding the hydrophobic TMD to increase solubility.

3.1: Does TA protein ubiquitination affect folding?
Ubiquitination of nascent TAs does not route for degradation, so I set out to find
what impacts ubiquitin may have on nascent TA proteins. Many TA proteins form strong
interactions with binding partners at various membranes. VAPA for example forms a
dimer either with another VAPA or VAPB (Nishimura et al., 1999). However, it would
be detrimental to the insertion process if such dimers formed between nascent TA
proteins still in the cytosol. How do cells prevent nascent TA proteins from binding to
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partners prior to proper membrane insertion? I reasoned that perhaps TA proteins are not
fully folded in the cytosol due to their ubiquitination. This unfolded-ubiquitinated state
would not recognize and interact with binding partners. Precedent exists for ubiquitindependent fold destabilization (Morimoto et al., 2016). Although, the example from
Morimoto et al. likely facilitates substrate unfolding prior to proteasomal degradation.
Could such effects on folding control protein activation and interactions? I first set out to
determine the folding status of nascent TA proteins. Trypsin is an enzyme that digests
proteins into fragments. Trypsin can be used to determine folding status because wellfolded proteins take longer to digest than unfolded proteins (Coulter-Mackie and Lian,
2008). I purified VAPA from cytosol or membrane fractions and VAPAΔTMD from the
cytosol. I previously showed that ubiquitinated VAPA resides in the cytosol and that
neither VAPA from a membrane fraction or VAPAΔTMD are ubiquitinated (Fig. 9B and
10A). Therefore, I subjected these different VAPA populations to trypsin treatment to
determine if ubiquitination could affect the rate of trypsin digestion (Fig. 28C). No
significant difference in the rate of digestion by trypsin was detected in the different
VAPA samples (Fig 28A and 28B).
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Figure 28: Whether ubiquitinated or not, Trypsin digestion shows no difference
between TA proteins.

Figure 28: (A) VAPA from a membrane fraction, VAPA from a cytosol fraction, or
VAPAΔTMD from the cytosol were immunoprecipitated from radiolabeled cells. The
immunoprecipitants were treated with the indicated concentrations of trypsin and
analyzed via autoradiography gels. (B) VAPA was analyzed as in A. (C) A diagram of
how trypsin digests unfolded proteins at a faster rate than it digests folded proteins.
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Trypsin digestions can be tricky since many variables can affect the digestion
rate. Therefore, I turned to a more binary method of digestion. The protein Dihydrofolate
reductase (DHFR) serves as a powerful tool to determine folding status because it
becomes tightly folded and digestion resistant when it binds its ligand tetrahydrofolate
(THF) (Fig. 29C) (Shi et al., 2019). I constructed a TA protein model substrate by
attaching the VAMP2 TMD to the C terminus of DHFR. DHFR-VAMP2 was
ubiquitinated in the cytosol and inserted and glycosylated at the ER as expected for a TA
protein suggesting that the attached TMD serves its purpose without causing misfolding
or degradation (Fig 9C, 29A, and 29B). Radiolabeled DHFR-VAMP2 was purified from
either the cytosol or the membrane fraction. There were no noticeable differences in
trypsin-sensitivity between the two fractions (Fig. 29A). Next, I added a DHFR ligand,
Methotrexate (MTX), which has similar affects in causing DHFR to tightly fold as the
above-mentioned THF. I reasoned that if ubiquitination affects the folding of TA
proteins, then ubiquitinated DHFR-VAMP2 may not properly bind to MTX and gain
protease protection. When exposed to MTX, cytosolic DHFR-VAMP2, membrane
DHFR-VAMP2, and wildtype DHFR all folded into a proteinase K resistant form (Fig.
29B). Therefore, I concluded that nascent TA proteins are well folded regardless of
localization or ubiquitination.
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Figure 29: TA proteins are well folded.
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Figure 29: (A) The TMD from VAMP2 was appended to the C terminus of DHFR.
DHFR-VAMP2 was immunoprecipitated from the cytosol or membrane. WT DHFR was
immunoprecipitated as a control. The radiolabeled immunoprecipitants were treated with
the indicated concentrations of trypsin and analyzed by autoradiography gels. (B) DHFR
constructs were purified as in A. The DHFR ligand, MTX, was added to fold DHFR into
a protease resistant form. Proteinase K was added to digest loosely folded or unfolded
DHFR. Samples were examined as in A. (C) A diagram detailing DHFR folding and
protease protection.

3.2: The role of ubiquitination in TA binding factors
Many ubiquitin-binding factors exist in the cytosol, so I hypothesized that there
could be ubiquitin-specific machinery acting within the TA insertion pathway. In Chapter
2, I discovered two novel factors, USP20 and USP33, that act on ubiquitinated TA
proteins at the membrane. I now ask if there are unknown factors that act on ubiquitinated
TA proteins in the cytosol. One possible candidate is the ATPase, P97/VCP. P97 is
known to bind and apply force to ubiquitinated proteins. This force can be used to
dissociate a ubiquitinated substrate from its binding partner (Prakash and Matouschek,
2004; van den Boom and Meyer, 2018). Co-expressing a dominant negative mutant P97
with β-VAMP2 resulted in loss of the model TA insertion (Fig. 30A). This loss of
insertion was observed for both β-VAMP2 and VAPA. As expected, lysine-free βVAMP2 did not show loss of insertion when the P97 mutant was co-expressed (Fig.
30B). Overexpressing the dominant negative form of P97 may cause general protein
homeostasis stress in cells since P97 plays important roles in ubiquitin-mediated
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proteasomal degradation. Such a general stress would likely affect β-VAMP2 and βVAMP2 lysine-free mutant equally. Next, β-VAMP2 or β-VAMP2ΔK and either vector
or P97 dominant negative mutant were co-expressed. β-VAMP2 and β-VAMPΔK were
radiolabeled and immunoprecipitated. Based on the glycosylation of the TA model
substrates at the ER, it appears that P97 dominant negative mutant hinders the insertion
of β-VAMP2, but not that of β-VAMPΔK (Fig. 30C). β-VAMP2ΔK is not ubiquitinated
because it lacks lysine residues necessary for ubiquitin conjugation (Fig. 30E). Therefore,
P97’s impact on TA protein insertion is likely ubiquitin dependent. To determine if this
effect is be due to overexpression of the P97 mutant, I performed siRNA knockdown of
P97. This disrupts P97 activity without possible gain-of-function issues of protein
overexpression. When P97 is knocked down, VAPA insertion is impaired (Fig. 30D).
P97 function requires other proteins including a deubiquitinase YOD (Ernst et al., 2009).
To determine if the observed effects on TA protein insertion were specific to the function
of P97, YOD was depleted via siRNA knockdown. Again, a loss in insertion of βVAMP2 was observed while β-VAMP2ΔK was unaffected (Fig 30F). I hypothesize that
P97 can bind to ubiquitinated TAs directly while they are being routed to the ER. Perhaps
P97 can exert force on the ubiquitinated TAs to help control their transfer from one
chaperone to the next in the insertion pathway (Fig. 30G). More experiments are needed
to determine P97’s possible role in TA protein synthesis.
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Figure 30: Disrupting P97 impacts TA protein insertion in a ubiquitin-dependent
manner.

Figure 30: (A) β-VAMP2 was expressed without or with a dominant negative P97
mutant (P97QQ) in HEK293 cells. The cells were radiolabeled and harvested in RIPA
buffer. β-VAMP2 was immunoprecipitated and analyzed via autoradiography. (B) The
indicated TA proteins were expressed without or with P97QQ. The TA proteins were
immunoprecipitated and examined for insertion based on glycosylation (denoted by the
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orange circles) by western blot analysis. (C) β-VAMP2 and β-VAMP2ΔK were
compared as in A. ImageJ was used to quantify the band intensity to determine the
glycosylation percentage. (D) siRNA was used to knockdown P97. VAPA was
immunoprecipitated and examined as in B and the glycosylation was quantified as in C.
(E) β-VAMP2 or β-VAMP2ΔK were immunoprecipitated from HEK293 cells.
αUbiquitin was used in western blot analysis to show the ubiquitination status of the two
TA proteins. (F) YOD siRNA was used to knock down YOD. β-VAMP2 and βVAMP2ΔK were compared as in C. (G) A diagram showing one possible way P97 may
be acting on TA proteins. P97 may pull ubiquitinated TA proteins from BAG6 to allow
the TA protein to escape the degradation route and return to the TA protein insertion
pathway.

3.3: Discussion
What role does the ubiquitination of TA proteins play in TA protein insertion?
Digestions of TA proteins show no difference in folding based on localization and
ubiquitination. However, shifts in folding may be below the detection limit of such
assays. First, only about 8% of TA proteins are ubiquitinated at any given time in the
cytosol (Fig 11E). A next step could be to further purify the cytosol membrane to only
examine ubiquitinated TA proteins. Also, it is possible that shifts in folding due to
ubiquitination could affect protein interactions without noticeably changing digestions
rates. Ubiquitin-mediated fold destabilization appears to be limited to regions near the
site of ubiquitination (Hagai and Levy, 2010). However, such changes in folding kinetics
due to ubiquitination are still relatively unclear.
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Furthermore, the insertion of TA proteins is impacted by the presence of lysine
residues likely due to ubiquitination. In figures 18 and 19, I showed that the TA protein
USP19 could compete with other TA proteins for insertion, but this competition was less
noticeable for lysine-free TA proteins. In figure 30, I show that disruption of P97 impairs
the insertion of TA proteins, with less of an effect on lysine-free (and thus not
ubiquitinated) TA proteins. I hypothesize that ubiquitin-binding factors such as P97 have
a yet-to-be discovered role in the insertion of TA proteins, and ubiquitination of TA
proteins could influence which factors bind and how the TA protein is handled.
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Chapter 4: TA protein synthesis is impaired during
protein homeostasis stress.
Protein misfolding diseases are often age related and can have a severe impact on
lifespan and quality of life. Protein misfolding diseases include a wide range of
pathologies such as Parkinson’s Disease, Huntington’s Disease, and retinitis pigmentosa
(Dobson, 2001). Aging and protein homeostasis are closely tied factors in human health
and it has been predicted that protein folding diseases will become more prevalent
considering the increasing trend in life-expectancy (Ventura, 2015). These diseases share
common hallmarks of protein misfolding, aggregation, and the accumulation of
misfolded proteins in the affected tissues such as the brain (Soto and Estrada, 2008). The
exact cause of cytotoxicity that results from protein folding diseases has been contested.
The most likely culprit for cell-death is the toxic gain of functions resulting from
aggregates and misfolded intermediates interfering with vital cellular processes (Soto and
Estrada, 2008). However, cytotoxicity is not the only factor to consider in human health;
we must also understand how cellular function is hindered by protein misfolding. If
particular cellular pathways are impaired under stress conditions, then identifying these
may provide therapeutic targets. For example, increasing neuron function in
neurodegenerative-disease patients may provide increased lucidity, though not a cure for
the cytotoxicity.
One cellular pathway that may be particularly susceptible to protein misfolding
diseases is the post-translational insertion of membrane proteins. As opposed to the
canonical co-translational insertion of membrane proteins, certain membrane proteins are
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released into the cytosol and must be post-translationally inserted into the proper
membrane. Co-translational insertion covers the majority of membrane proteins and is
mediated by the signal recognition particle (SRP). SRP recognizes nascent peptides
bound for the ER and direct the entire ribosome complex to the ER membrane (Walter
and Johnson, 1994). Once there, the nascent peptide is inserted directly into the ER
membrane by the Sec61 translocon channel thus avoiding exposure to the cytosol.
Although a small population relative to co-translationally produced membrane
proteins, post-translationally inserted membrane proteins are vital for cellular and
organelle function. Post-translational insertion is required for ER tail-anchored proteins
and mitochondrial membrane proteins. Special machinery is required to recognize, triage,
chaperone, and insert these membrane proteins. The machinery includes a multitude of
chaperones because transmembrane domains are hydrophobic and must be protected.
Exposed hydrophobic domains are repelled by the aqueous cytosol and form harmful
interactions and aggregates.
Chaperones are proteins capable of binding other proteins to shield hydrophobic
domains thus improving solubility. In addition to solubility efforts, chaperones aid in
protein trafficking, disaggregation, and folding. Interestingly, some chaperones are
capable of performing multiple functions and act within multiple pathways. For example,
HSP70 is a class of chaperone that functions in folding and targeting nascent proteins and
the disaggregation and degradation of misfolded proteins (Fernandez-Fernandez et al.,
2017). SGTA has been shown to bind nascent TA proteins, mislocalized proteins, and the
proteasome (Leznicki et al., 2015; Thapaliya et al., 2016; Wunderley et al., 2014)
Another example of a multifunctional chaperone is BAG6. The BAG6 complex plays an
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important role in shielding and targeting tail-anchored membrane proteins to the ER
(Mariappan et al., 2010). However, BAG6 also binds mislocalized proteins and the E3
ligase RNF126. RNF126 ubiquitinates mislocalized substrates and BAG6 maintains
solubility and aids in targeting to the proteasome (Hessa et al., 2011). Such
multifunctional chaperones may help cells adapt to changing environments by keeping
the cell prepared for rapid protein synthesis or degradation as needed. On the other hand,
could using the same chaperone for different functions have deleterious effects? Under
chronic stress as seen in protein folding diseases, failure to maintain protein homeostasis
results in the accumulation of misfolded proteins. Chaperones bind to these misfolded
proteins and localize to aggregates to protect cells. How does the accumulation of
misfolded proteins affect cellular pathways which rely on the same chaperones?
In Chapters 2 and 3, I show that nascent TA proteins are ubiquitinated. Despite
the ubiquitination, these TA proteins are not recognized for ubiquitin-mediated
proteasomal degradation. Instead, the ubiquitinated TA proteins are able to route to the
ER membrane where they are inserted and deubiquitinated (Culver and Mariappan,
2021). These experiments were performed in healthy cells. However, could TA protein
synthesis be hampered during protein homeostasis stress? The TA protein insertion
pathway has been described as a chaperone relay (Cho and Shan, 2018). Multiple
chaperone steps allow for specificity in capturing and inserting TA proteins (Shao et al.,
2017). However, these chaperones may become over-burdened during stress conditions
and fail to properly handle TA proteins. To artificially cause protein homeostasis stress in
cells, I used MG132 to inhibit the proteasome. Proteasome inhibitors are therapeutically
relevant tools which are actively used to treat for certain kinds of cancer (Guo and Peng,
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2013; Ito, 2020; Wente et al., 2005). Understanding how protein synthesis is affected
when the proteasome is blocked is physiologically relevant as a comparison to certain
protein folding diseases, such as Huntington’s Disease and amyotrophic lateral sclerosis
(Bence et al., 2001; Guo et al., 2018). Since chaperones like SGTA and BAG6 are
important for both TA protein synthesis and misfolded protein degradation, I
hypothesized that the post-translational targeting of TA proteins will be impaired during
protein homeostasis stress due to overburdened chaperones.

4.1: TA protein translation and insertion are hampered during protein
homeostasis stress.
To test if protein homeostasis stress impacts TA protein synthesis, I treated cells
overexpressing β-VAMP2 with MG132 to block the proteasome. Radiolabeled βVAMP2 was immunoprecipitated and the inserted/glycosylated form was less abundant
compared to β-VAMP2 from healthy cells. Next, samples were treated with Endo H to
remove the N-glycosylation. This allowed me to compare the total β-VAMP2 that was
immunoprecipitated, and less total TA protein was present after stress (Fig. 31A). I then
asked if these phenotypes generally occurred on all proteins or if this is specific to posttranslationally inserted proteins. I compared the glycosylation of two TA substrates,
SEC61β and β-VAMP2, with a luminal co-translationally inserted substrate, antitrypsin.
Under stress conditions, the TA proteins exhibited a loss in total protein and insertion
while antitrypsin was relatively unaffected (Fig. 31B). Since antitrypsin could still be
translated and glycosylated normally under stress conditions, I reasoned that the loss of
TA protein abundance and insertion is linked to the post-translational insertion pathways
for TA proteins. To track this over time, I pre-treated cells with MG132 to disrupt protein
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homeostasis. Then, I immunoprecipitated β-VAMP2 after different chase time points.
After allowing the cells two hours of chase time, I found that 80% of the β-VAMP2 was
glycosylated in healthy cells while about 60% were in cells under stress (Fig. 31C). This
chase was repeated in triplicate and quantified to show that MG132 consistently delayed
TA protein insertion (Fig. 31D). Lastly, a range of TA proteins were subjected to similar
untreated versus MG132 treated conditions (Fig. 31E). The substrates are ordered based
on the hydrophobicity of their TMDs with the far left being the most hydrophobic. Could
TA proteins with more hydrophobic TMDs be most impacted by MG132 treatment?
Experiments using the same TA protein with mutations in the TMD to vary
hydrophobicity could shed light on the importance of TMD hydrophobicity during
protein homeostasis stress.

87

Figure 31: Stress disrupts the insertion of TA proteins.

Figure 31: (A) Cells expressing β-VAMP2 were treated without or with MG132 and then
radiolabeled. Cells were lysed with RIPA buffer and β-VAMP2 was immunoprecipitated.
The immunoprecipitated samples were treated with Endo H and examined by
autoradiography gel electrophoresis. (B) The indicated proteins were examined as in A.
(C) β-VAMP2 was expressed and radiolabeled in HEK293 cells. The cells were rinsed
and chased for the indicated times. β-VAMP2 was examined as in A. (D) ImageJ
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software was used to quantify the intensity of the bands from C and two replicates of C.
The quantified values were graphed in Prism to track the rate of insertion/glycosylation
of β-VAMP2. (E) The indicated proteins were examined as in A.

Protein homeostasis can be perturbed in many ways whether in patients due to
diseases and/or environmental factors or in cell culture with various stress-inducing
agents. I next compared the effects on TA proteins synthesis after treatment with the
proteasome blocker, MG132, or the HSP70 inhibitor, Pifithrin-µ (PFT). PFT is a small
molecule that causes the accumulation of misfolded and aggregated proteins in cells by
directly binding to and inhibiting HSP70 (Leu et al., 2009). Curiously, PFT did not
inhibit TA protein synthesis unlike MG132 (Fig. 32A). More tests and a positive control
for PFT treatment are needed to determine if PFT would harm TA synthesis at higher
concentrations or if loss of TA synthesis is specific to certain types of protein
homeostasis stress.
Both TA protein abundance and insertion appear to be impaired after treatment
with MG132. The loss of TA proteins harvested from cells could be due to insoluble
aggregation, cell death, or lowered translation during stress. Furthermore, examining the
loss of TA protein insertion phenotype is complicated by the loss of total protein.
Therefore, I tested if the loss of TA protein was due to translation inhibition during stress.
I introduced ISRIB, integrated stress response inhibitor, treatment to the cells. The
proteins eIF2 and eIF2B work cooperatively to deliver the initial t-RNA needed for
translation to the ribosome. However, under stress conditions, eIF2 is phosphorylated and
undergoes a conformational change that inhibits eIF2B (Kimball, 1999). ISRIB is a drug
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that binds to eIF2B and allows it to function even under stress when eIF2 is
phosphorylated (Zyryanova et al., 2021). I found that MG132 did not decrease TA
protein yield when combined with ISRIB treatment. Thus, ISRIB rescued TA translation
under stress conditions (Fig. 32B). I then quantified and compared the percentage of
glycosylated/inserted TA protein. Without the masking effect of inhibited translation, I
calculate that TA insertion is approximately 30% less efficient when cells are treated with
MG132 (Fig. 32B and 32C). Although additional repeats are needed to determine the
reproducibility of this estimation.

Figure 32: MG132 slows both TA protein translation and insertion.
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Figure 32: (A) Cells expressing β-VAMP2 were treated with either 20 µM MG132 or 20
µM Pifithrin-µ (PFT) for the indicated times and radiolabeled. The cells were harvested
in RIPA buffer and β-VAMP2 was immunoprecipitated via its FLAG tag.
Autoradiography gel electrophoresis was used to examine the β-VAMP2. (B) Cells were
treated without or with 20 µM MG132 and 4 µM integrated stress response inhibitor
(ISRIB). β-VAMP2 was examined as in A. (C) ImageJ software was used to quantify the
intensity of the bands from B. The quantified values were graphed in Prism to compare
the effects of the treatments.

4.2: TA insertion machinery is affected by protein homeostasis stress.
Above, I found that TA insertion is inhibited during protein homeostasis stress.
Both TA proteins and misfolded proteins contain exposed hydrophobic regions and are
ubiquitinated. Furthermore, factors responsible for TA insertion have been shown to
function for protein degradation as well. The similarities and shared chaperones between
TA proteins and misfolded proteins could be the cause for the impaired TA insertion
during stress. Specifically, could accumulated misfolded proteins bind vital TA insertion
machinery and block TA synthesis?
First, I asked what effects protein homeostasis stress could have on the known
factors in the TA insertion pathway. An integral aspect of the TA insertion pathway is the
binding and subsequent release of the nascent TA substrate. The chaperones involved
must accurately capture and then hand-off the TA protein. Could the accumulation of
misfolded proteins impede on this process? I immunoprecipitated overexpressed BAG6
in untreated or MG132-treated cells and found that SGTA-BAG6-TRC40 binding was
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stabilized under stress conditions (Fig. 33A). The same increase in BAG6-TRC40
interaction is observed when immunoprecipitating overexpressed TRC40 (Fig. 33A).
This is a bad sign for TA protein insertion, because the SGTA-BAG6-TRC40 interaction
is a transient one meant to dissolve after proper TA protein transfer to TRC40. To verify
that the stabilized interactions were not due to BAG6 overexpression, I repeated the
experiment in cells with a 3xFLAG tag appended to endogenous BAG6. Even at
endogenous levels, I found that SGTA-BAG6-TRC40 were more tightly bound during
stress conditions (Fig. 33B).
Since the TA insertion pathway exhibits a shift in binding kinetics, I next asked
where are nascent TA proteins during such a stress? Are they abandoned in the cytosol or
perhaps trapped at a particular step in the insertion pathway? Therefore, I
immunoprecipitated β-VAMP2 and examined the chaperones that were pulled-down with
it. I found that β-VAMP2 co-immunoprecipitated TRC40 at similar levels in healthy cells
compared to MG132 treated cells. SGTA was not detected in either sample from WT
cells. Interestingly, more BAG6 was co-immunoprecipitated during stress (Fig 33C).
This could be caused by β-VAMP2 binding the BAG6-TRC40 complex without properly
transferring onto TRC40 and/or β-VAMP2 being transferred to TRC40 without proper
release of TRC40 from BAG6. SGTA binding could only be detected in the BAG6 KO
cells (Fig 33C) likely because SGTA is upstream of BAG6 and the transfer to TRC40 is
slowed without BAG6 to assist. Interestingly, β-VAMP2 binding to both SGTA and
TRC40 decreased under stress conditions in BAG6 KO cells (Fig 33C). Digitonin was
used for these experiments because it is a milder detergent that does not disrupt
hydrophobic protein-protein interactions. However, when comparing digitonin to a
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stronger detergent, TX-100, the stress dependent nature of TRC40-BAG6 binding
kinetics changes. With TX-100, I observed the inverse pattern with TRC40 binding
tightly to BAG6 until stress disrupts the interaction (Fig. 33D). I hypothesize that the
different detergents determine whether or not TA proteins and misfolded proteins are coimmunoprecipitated with the BAG6 and that the presence of both misfolded and TA
proteins might shift TRC40-BAG6 binding. However, more experiments are needed to
determine how stress affects the binding kinetics of these chaperones.
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Figure 33: Stress disrupts the binding kinetics of TA protein insertion machinery.

Figure 33: (A) HEK293 cells overexressing BAG6-FLAG were treated without or with
MG132 and harvested in digitonin buffer. BAG6 was immunoprecipitated. Western blot
analysis was used to examine the indicated proteins. (B) HEK293 cells genetically
modified with a 3xFLAG tag added to endogenous BAG6 were treated and examined as
in A. (C) WT or BAG6 KO Cells transfected with β-VAMP2 were treated and examined
as in A. (D) Cells transfected with BAG6-FLAG were treated with MG132 for the
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indicated times. Cells were harvested with either digitonin or TX-100 and then examined
as in A.

During protein homeostasis stress, protein aggregates form since the cell cannot
properly degrade misfolded proteins. Chaperones are recruited to these aggregates in an
attempt to shield the exposed hydrophobicity from the cytosol. Could the stressdependent loss of TA protein insertion be due to chaperones localizing to aggregates and
not being able to effectively traverse the cytosol with their TA protein cargo? I treated
cells with MG132 for up to 8 hours. Since protein aggregates fall out of solution, they are
also detergent-resistant allowing me to separate soluble proteins from these aggregates. I
found that BAG6, HSP70, β-VAMP2, and possibly TRC40 localize to aggregates during
stress conditions (Fig. 34A). If these proteins are localized to aggregates during stress,
then they likely are not able to help nascent TA proteins reach the ER.
BAG6 can bind directly to misfolded proteins and has been shown to play a role
in protein degradation (Claessen et al., 2014; Hessa et al., 2011; Kawahara et al., 2013).
Therefore, I hypothesized that BAG6 could be the main factor that is dysfunctional
during stress conditions. BAG6 has been shown to triage misfolded proteins for
degradation and remove them from the TA protein insertion machinery (Ganji et al.,
2018; Leznicki and High, 2012; Shao et al., 2017). Without BAG6 to remove misfolded
proteins, perhaps SGTA and TRC40 become occupied by misfolded proteins thus
abandoning nascent TA proteins, explaining the loss in binding to β-VAMP2 observed in
BAG6-KO cells under stress (Fig. 33C).
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BAG6 binds misfolded and ubiquitinated proteins and SGTA-BAG6-TRC40
binding is impacted by the accumulation of misfolded proteins. Is the shift in binding
directly caused by BAG6 binding misfolded proteins? Thanks to previous structural and
functional studies on BAG6 (Kuwabara et al., 2015; Leznicki et al., 2013; Mock et al.,
2015), I was able to create a mutant of BAG6 that can bind SGTA and TRC40 without
binding misfolded proteins. The N terminus of BAG6 has been shown to interact with
ubiquitinated proteins and the C terminus serves as the scaffold for UBL4a, TRC35,
SGTA, and TRC40 (Hessa et al., 2011; Minami et al., 2010; Wang et al., 2011).
Therefore, BAG6ΔN only contains the parts relevant for TA protein insertion while
BAG6ΔC only contains the ubiquitin-binding functions. I immunoprecipitated a variety
of BAG6 constructs under healthy or MG132-treated conditions. Again, I observed an
increase in binding among SGTA, TRC40, and BAG6 after MG132 treatment, and
wildtype BAG6 co-immunoprecipitated ubiquitinated proteins (Fig. 34B). As expected,
BAG6ΔN did not interact with ubiquitinated proteins. However, there was still a stressdependent increase in BAG6ΔN binding to SGTA and TRC40 even without
ubiquitinated-protein binding. Thus, the mutant BAG6ΔN does not successfully prevent
protein homeostasis stress from impacting the TA insertion pathway. BAG6 also
localizes to protein aggregates, so I tested BAG6ΔN and found much lower proteinaggregate localization as compared to wildtype BAG6 (Fig 34C).
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Figure 34: BAG6 interacts with misfolded ubiquitinated proteins.

Figure 34: (A) HEK293 cells
expressing β-VAMP2 were treated
with MG132 for the indicated times.
The cells were lysed with TX-100, and
the lysates were centrifuged. The
supernatant corresponds with the TX100 soluble lanes. The pellets were
solubilized in SDS buffer and
correspond with the insoluble lanes.
Western blot analysis of the indicated
proteins was used to track soluble
versus insoluble populations. (B) Cells
expressing the indicated BAG6
constructs were treated without or with
MG132. Cells were harvested using
digitonin, and BAG6 was
immunoprecipitated. Western blot
analysis was performed on
immunoprecipitated samples for the
indicated proteins. (C) Cells expressing
either BAG6 or BAG6ΔN were examined as in A.
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Since BAG6 serves multiple functions by both aiding in protein degradation and
in TA protein synthesis, could BAG6 be a limiting factor causing the loss of TA protein
insertion efficiency during stress? I tracked the insertion of β-VAMP2 using Nglycosylation as a marker as previously in Figure 16. This time, I compared wildtype
cells with BAG6 KO cells. If BAG6 is the limiting factor for TA synthesis during stress,
then β-VAMP2 insertion should not be noticeably lost when comparing untreated to
MG132-treated BAG6 KO cells. I found that β-VAMP2 insertion is impaired in both
wildtype and BAG6 KO cells during stress (Fig. 35A). I quantified the percentage of
inserted β-VAMP2 over time and graphed the results (Fig. 35B). As expected, β-VAMP2
was inserted at a slower rate in untreated BAG6 KO cells as compared to wildtype cells
likely due to the loss of BAG6 disrupting the TA insertion pathway. Interestingly, βVAMP2 insertion was decreased in both wildtype and BAG6 KO cells after treating with
MG132. Though the loss of insertion was less severe in BAG6 KO cells, the wildtype
cells and BAG6 KO cells showed similar insertion rates after stress.
Since knocking out BAG6 disrupted TA protein insertion even in healthy cells, I
next rescued BAG6 expression with either wildtype BAG6 or BAG6ΔN. I reasoned that
if BAG6 is limiting due to stress conditions, then overexpressing it will rescue the loss of
insertion efficiency. Furthermore, overexpressing BAG6ΔN should rescue TA protein
insertion during stress if the issue is caused by BAG6 binding misfolded and aggregated
proteins. I found that loss of β-VAMP2 insertion occurred regardless of BAG6
overexpression or mutation (Fig. 35C). I quantified the percentage of inserted β-VAMP2
in the BAG6 and BAG6ΔN cells and graphed the changes over time (Fig. 35D). TA
protein insertion is similarly impaired during protein homeostasis stress regardless of
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BAG6 status. I next checked if SGTA or TRC40 could be limiting factors for TA
insertion. I overexpressed SGTA, BAG6, or TRC40 and examined the insertion
efficiency of β-VAMP2 (Fig. 35E). TRC40 overexpression increased β-VAMP2
insertion in healthy cells. However, β-VAMP2 insertion efficiency was impaired by
MG132 regardless of chaperone overexpression.

Figure 35: Stress-induced loss of TA protein insertion is not directly due to lack of
available chaperones.
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Figure 35: (A) Cells expressing β-VAMP2 were treated without or with MG132,
radiolabeled, and chased. β-VAMP2 was immunoprecipitated and examined via
autoradiography gel electrophoresis. (B) The intensities of the autoradiography protein
bands from A were quantified in ImageJ and graphed in Prism. (C) Cells expressing βVAMP2 were also transfected with vector, BAG6, or BAG6ΔN. β-VAMP2 was
examined as in A. (D) C was quantified and graphed as in B. (E) β-VAMP2 from cells
also transfected with SGTA, BAG6, or TRC40 was examined as in A.

4.3: Discussion
I have shown that TA protein insertion into the ER can be impaired during
proteotoxic stress. This applies to proteasome inhibition via MG132 treatment but not
HSP70 inhibition via PFT treatment. Further study and different treatments are needed to
determine if the loss of insertion efficiency phenotype is due to accumulated misfolded
proteins or due to features specific to MG132. Furthermore, the binding patterns of
nascent TA proteins and their related factors are affected by proteotoxic stress. TA
protein insertion factors such as BAG6 and SGTA can bind to exposed hydrophobicity of
misfolded proteins and act as chaperones. Misfolded proteins accumulate during
proteotoxic stress, so I hypothesize that misfolded proteins bind to important TA protein
insertion machinery and slow the pathway. I observed impaired TA protein insertion in
cells under protein homeostasis stress. However, increasing the availability of SGTA,
BAG6, or TRC40 did not rescue TA protein insertion under stress (Fig. 35E). The link
between proteotoxic stress disrupting both insertion of TA proteins and the binding
kinetics of the pathway is intriguing. An important next step for chapters 2-4 is to
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examine ubiquitin-dependent TA-protein-binding factors. If TA ubiquitination recruits
unknown ubiquitin-binding chaperones, then these likely play a role in how protein
homeostasis stress affects TA protein synthesis.
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Chapter 5: A link between TA protein synthesis and Olinked glycosylation
Cells ensure proper protein production, folding, trafficking, and degradation
through precise monitoring and regulation of protein homeostasis. A wide range of issues
including oxidative stress, protein misfolding, and protein mislocalization can disturb
protein homeostasis. This leads to aggregate-prone proteins accumulating, proteotoxicity,
and apoptosis. Disruption of protein homeostasis is detrimental to proper cell function
and has been linked to multiple human disorders including aging diseases such as
Alzheimer’s, type II diabetes, and cancers (Dai et al., 2007; Ozcan et al., 2006; Zhang et
al., 2004). Multiple pathways exist within eukaryotic cells to compensate for such stress:
the unfolded protein response (UPR) of the endoplasmic reticulum, the UPR of the
mitochondria, and the heat shock response pathways are three examples. These stress
response pathways sense the accumulation of aggregate-prone proteins and adjust the
expression and function of proteins such as chaperones.
One such chaperone, BAG6, can capture and maintain the solubility of misfolded
proteins. BAG6 is associated with multiple functions, including the shielding and
trafficking of nascent misfolded polypeptides, ERAD substrates, and nascent tailanchored membrane proteins (Claessen et al., 2014; Kawahara et al., 2013; Mariappan et
al., 2010). The BAG6 complex triages a range of different substrates to either be
degraded or inserted into a membrane (Shao et al., 2017). Since BAG6 can bind
misfolded proteins, then it may cooperate with other factors to sense protein homeostasis
stress. BAG6 could assist OGT in sensing stress. OGT, O-GlcNAc transferase, adds O-
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linked glycosylation to proteins and is a nutrient and stress sensor (Lefebvre et al., 2010).
O-linked glycosylation is a transient protein modification added by OGT and removed by
OGA, O-GlcNAcase (Yang and Qian, 2017). The BAG6-OGT interaction was found via
a yeast two-hybrid screen (Cheung et al., 2008). Another study showed about 4% of
BAG6 was mono-glycosylated by OGT in HEK293T cells (Teo and Wells, 2014).
However, any possible roles of the BAG6-OGT interaction remain unclear.
OGT gains substrate specificity via protein-protein interactions with adaptors
(Cheung et al., 2008; Nagel and Ball, 2014). However, the substrates modified by OGT
while bound to BAG6 are not known. Additionally, it is unclear how BAG6 functions
under stress condition to aid in cell survival. My thesis research further characterized the
BAG6-OGT interaction and its response to stress. I hypothesize that O-GlcNAcylation of
the BAG6 complex may aid BAG6-substrate solubility and delivery, while removal of OGlcNAc leads to BAG6 substrate degradation. This model would allow BAG6 to quickly
adjust function in response to stress, thus improving cell viability.

5.1: BAG6 binds OGT
Preliminary data from Dr. Mariappan showed that BAG6 binds to OGT (Fig.
36A). In this detergent-free purification of BAG6 from rabbit reticulocytes, we see
TRC40, SGTA, TRC35 and UBL4A as expected. However, the interaction with OGT is
novel and intriguing due to OGT’s ability to modify proteins with O-linked
glycosylation. I verified the interaction between BAG6 and OGT in human cells by
transfecting HEK293 cells with OGT. BAG6 co-immunoprecipitated with the OGT (Fig.
36B). I performed the reverse by transfecting in BAG6 and found OGT coimmunoprecipitated with BAG6 (Fig. 36C).
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Figure 36: BAG6 interacts with O-linked N-acetylglucosamine transferase (OGT).

Figure 36: (A) BAG6 was purified from rabbit reticulocyte lysate in a detergent-free
buffer. The samples were examined via Coomassie-gel staining. A control antibody was
used to determine which bands are nonspecific. (B) HEK293 cells were transfected with
OGT-FLAG and harvested with digitonin. OGT was immunoprecipitated and the samples
were examined via western blot analysis. (C) BAG6 was immunoprecipitated and
examined as in B.

The data from Figure 34 as well as previous studies have shown that different
regions of BAG6 have been implicated in varied functions and pathways. For example,
the C-terminal end of BAG6 binds to important factors for TA membrane protein
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targeting while the N-terminal end contains a ubiquitin-like domain which serves a role
in ER associated degradation (Mock et al., 2015; Xu et al., 2013). Therefore, discovering
the interacting region between BAG6 and OGT could provide key insights into the
function of the interaction. I performed site-directed mutagenesis to delete a variety of
BAG6 regions. I immunoprecipitated the BAG6 mutants and found that deletion of only
35 amino acids (BAG6Δ556-590) abolished the interaction with OGT (Fig. 37A). Future
experiments will express only a small stretch of BAG6 (~500-650 AA) to determine if
this region of BAG6 is both necessary and sufficient to bind with OGT. The 556-590AA
region of BAG6 resides within the proline-rich and flexible region of BAG6 (Fig. 37B).
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Figure 37: BAG6 amino acids 556-590 are required for OGT interaction.
Figure 37: (A) The
indicated BAG6 deletion
constructs were produced
via staggered primer
PCR. The different
BAG6-FLAG mutants
were over expressed in
HEK293 cells. Coimmunoprecipitation
followed by western blot
analysis was used to
examine the OGT-BAG6
interaction. (B) Diagram
of the known regions of
BAG6 with the addition
of the information learned
from A. (C) Cells
expressing BAG6 were
treated with or without MG132. The cells were harvested in digitonin buffer without or
with NEM. The BAG6-OGT interaction was examined as in A.
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5.2: BAG6-OGT interaction is stress-sensitive
BAG6 assists in the degradation of misfolded proteins (Claessen and Ploegh,
2011; Hessa et al., 2011), and OGT is induced during protein homeostasis stress caused
by heat shock (Martinez et al., 2017). Could the interaction allow for BAG6 and OGT to
cooperate in response to protein homeostasis stress? I immunoprecipitated exogenous
BAG6 under MG132 treatment and with NEM (N-Ethylmaleimide). NEM modifies free
cysteines to inhibit proteases including deubiquitinases. This prevents deubiquitination
after cell lysis. However, I found that the inclusion of NEM also disrupts the BAG6-OGT
interaction. Furthermore, it appears that BAG6-OGT interaction might increase after
MG132 treatment when BAG6 is overexpressed (Fig. 37C).
Next, I asked if the BAG6-OGT interaction controls cellular levels of OGlcNAcylation. Could BAG6 be a regulator of OGT controlling total O-GlcNAc levels? I
harvested BAG6 KO cells, cells rescued with wildtype BAG6, or cells rescued with
BAG6Δ556-590 (OGT-interaction null mutant). I then examined the total protein sample
via western blot analysis for O-GlcNAcylated proteins. Neither the presence of BAG6 or
MG132 treatment noticeably shifted total O-GlcNAc levels in cells (Fig. 38A). However,
if OGT is modifying proteins bound to BAG6, then signal from this population may be
too low to detect in total lysates. Therefore, I immunoprecipitated BAG6. As in Figure
37C, I again found that the BAG6-OGT interaction was low when cells are lysed with
NEM, but BAG6-OGT binding increased after MG132 treatment (Fig. 38B).
Interestingly, I detected O-GlcNAcylated proteins bound to BAG6 after MG132
treatment. However, similar signal was observed when comparing BAG6 with
BAG6Δ556-590. This means that the signal is not dependent on the BAG6-OGT
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interaction. Furthermore, O-GlcNAc signal is lost in the BAG6ΔN sample. Therefore, it
is likely that the O-GlcNAcylated proteins bound to BAG6 are misfolded proteins
because the N-terminus of BAG6 binds misfolded proteins. Next, I immunoprecipitated
BAG6 again to examine bound O-GlcNAcylated proteins but this time during a CHX
chase (Fig. 38C). Total O-GlcNAcylated proteins increase after cycloheximide treatment.
Despite this total increase, the O-GlcNAc signal that immunoprecipitates with BAG6 is
decreased by CHX. This combined with the BAG6ΔN data lead me to reason that nascent
misfolded or mislocalized proteins are O-GlcNAc modified while bound to BAG6.
Although it is unclear how OGT reaches these substrates since the BAG6-OGT
interaction is dispensable for the observe O-GlcNAc signal.
Could nascent TA proteins be modified with O-GlcNAc via the BAG6-OGT
interaction? I immunoprecipitated VAPA while overexpressing OGT as well. However,
no O-GlcNAc signal was detected on VAPA (Fig. 38D). Nascent TA proteins transiently
reside in the cytosol as they are rapidly inserted into the ER membrane, and O-GlcNAc is
transient post-translational modification as OGT and OGA add and remove the
modification respectively. Therefore, the substrates modified in a BAG6-OGT dependent
manner may be quite difficult to purify and detect.

108

Figure 38: BAG6-OGT dependent glycosylation is not readily detectable.

Figure 38: (A) BAG6 KO cells alone or rescued with BAG6 or BAG6Δ556-590 were
treated with MG132 for the indicated times. The cells were harvested and the lysates
were examined via western blot analysis. (B) The indicated protein was expressed in
HEK293 cells treated without or with MG132. The BAG6 constructs were
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immunoprecipitated and the samples were examined via western blot analysis. (C) Cells
overexpressing BAG6 were treated with MG132 and cycloheximide (CHX) and
examined as in B. (D) Cells were transfected with OGT and either VAPA or VAPAΔK.
The VAPA was immunoprecipitated in RIPA buffer and examined via western blot
analysis.

5.3: Discussion
I have shown evidence of a previously uncharacterized interaction between BAG6
and OGT. This link between a chaperone and a post-translational modifier has interesting
implications. Could OGT bind to BAG6 to gain access to specific substrates? Examples
of OGT-regulators determining OGT specificity exist (Cheung et al., 2008; Nagel and
Ball, 2014). BAG6 is uniquely positioned at a crossroads between protein degradation
and synthesis and considerable efforts have focused on determining how BAG6
accurately triages substrates towards the correct fate (Ganji et al., 2018; Leznicki and
High, 2012; Shao et al., 2017). In Chapter 4, I found that TA protein insertion and related
chaperones are disrupted during proteotoxic stress. Therefore, in Chapter 5, I examined
whether OGT could be modifying BAG6 substrates to aid in modulating substrate triage
in response to environmental changes. This could be particularly interesting since OGT is
known to respond to stresses on the cell (Martinez et al., 2017), and here we observed
stress-dependent shifts in O-GlcNAcylation (Fig. 38C). The stress-induced increase in
BAG6-OGT binding was recently observed by others as well (Martinez et al., 2021).
However, Martinez et al. examined BAG6-OGT under oxidative stress conditions and
have not yet presented a function for the interaction.
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It remains technically difficult to explore possible functions of the BAG6-OGT
interaction due to the transient nature of both O-GlcNAc modifications and BAG6
substrates. O-GlcNAcylation is transient as OGT addes and OGA removes the
modification. BAG6 substrates are also transient as TA proteins are rapidly routed to the
ER and misfolded proteins are degraded. This transience issue may explain why I
detected minimal O-GlcNAcylated proteins bound to BAG6 (Fig. 38B, C, and D). On
the other hand, I may be investigating the wrong pathway. BAG6 serves a range of
functions other than TA protein and misfolded protein triage. The BAG6-OGT
interaction presented here may function in BAG6’s nuclear, autophagy, or mitophagy
roles (Hayashishita et al., 2019; Krenciute et al., 2013; Ragimbeau et al., 2021; Sebti et
al., 2014). Future experiments will cross-examine OGT and BAG6 substrates in search of
common targets.
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Chapter 6: Materials and methods
6.1: DNA constructs
pcDNA 3.1 (Thermo Fisher) or pCDNA5/FRT/TO (Invitrogen) vectors were used
for mammalian expression. To construct TA model substrates, PCR amplification of the
gene in question was performed with Phusion High-Fidelity DNA polymerase (Thermo
Fisher). A FLAG tag (MDYKDDDDK) was added to the N-terminal primers. For the
ER-targeted TA proteins, an opsin tag was added to the C-terminal primers as seen in
Fig. 9A. Restriction enzyme cut sites were also added to the primers to allow for
digestion (restriction enzymes from NEB) followed by ligation by T4 DNA Ligase
(NEB) into the vectors above. For VAPA ΔTMD, the amino acids from 227 to 249 were
deleted using phosphorylated primers with the Phusion Site-directed mutagenesis
protocol (Thermo Fisher). DHFR was a gift from Dr. Zai-Rong Zhang and cloned into the
pCDNA5/FRT/TO as above. For DHFR-VAMP-TMD, human VAMP2 TMD (amino
acids 91 – 114) was PCR amplified and inserted into the C-terminus of DHFR using a
standard cloning procedure. β-VAMP2 containing the cytosolic domain of SEC61β and
the TMD of VAMP2 was previously described (Mariappan et al., 2010). β-VAMP2 with
lysine mutations were generated using Pfu polymerase (Agilent Technologies) based sitedirected mutagenesis. To construct SEC61β - Hydrophobic VAMP2 TMD (β-VAMP2Hy), the indicated amino acids in Fig. 9A were replaced by site-directed mutagenesis.
Zebrafish mini-Otoferlin containing amino acids from 1495 to 1773 was gifted from Dr.
Erdem Karatekin and cloned into pCDNA5/FRT/TO with a FLAG and opsin tag as
above. Rabbit Cb5 was gifted from the Hegde lab and cloned into the pCDNA5/FRT/TO
as above with the addition of an N-terminal FLAG tag and a C-terminal opsin tag.
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FLAG-HA-USP20 (Addgene #22573) and FLAG-HA-USP33 (Addgene #22601) were
gift from Wade Harper. USP20 and USP33 were cloned into the pCDNA5/FRT/TO as
above with the addition of the N-terminal His-Strep-TEV sequence
(MHHHHHHASGGWSHPQFEKASENLYFQGVDGT). Two rounds of site-directed
mutagenesis were used to create catalytically inactive USP20 (C154S/H643Q) and
USP33 (C194S and H665Q) using Pfu polymerase. FLAG-XBP1u (Plumb et al., 2015)
was used as a template to create XBP1u mutant (L246A) using site directed mutagenesis.
PDI-FLAG was gift from David Ron (Addgene #31382). The coding sequences of all
constructs were verified by sequencing (Yale Keck DNA Sequencing Facility).

6.2: Antibodies and reagents
Antibodies used for immunoblotting are as follows: Mouse α-HA-HRP (Cell
Signaling, # 2999S), Rat α-FLAG L5 (BioLegend #12775), Rabbit α-FLAG, Rabbit αGFP, Rabbit α-RFP, Rabbit α-TRAPα, and Rabbit α-Sec61α are a gift from Dr.
Ramanujan Hegde. Rabbit α-SGTA, Rabbit α-BAG6, and Rabbit α-TRC40 have been
previously described (Mariappan et al., 2010; Shao et al., 2017). Mouse α-CAML
(Origene #TA504363), Rabbit α-USP19 (Invitrogen, # PA5-97239), Mouse α-USP30
(Santa Cruz, # sc-515235), Mouse α-Tubulin (Abcam, # ab7291), Goat α-Rat-HRP (Cell
Signaling, #7077), Goat α-Mouse-HRP (Jackson ImmunoResearch, #115-035-003), Goat
α-Rabbit-HRP (Jackson ImmunoResearch, #111-035-003), Goat α-Rabbit IgG-Cy3
(Jackson ImmunoResearch # 111-165-003), Goat α-Mouse IgG-Cy2 (Jackson
ImmunoResearch # 115-225-166), Goat α-Rabbit IgG-Cy2 (Jackson ImmunoResearch #
111-225-144), Goat α-RAT IgG-Cy2 (Jackson ImmunoResearch # 112-225-167), Goat αMouse IgG-Alexa 657 (Invitrogen # A-21235) or Goat α-Rabbit IgG-Alexa 647
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(Invitrogen # A27040), Rabbit α-USP20 (Proteintech, #17491-1-AP), Rabbit α-USP33
(Proteintech #20445-1-AP), Mouse α-USP33 (Sigma #WH0023032M1), Rabbit αCalreticulin (Affinity BioReagents # PA3-900), Mouse α-PDIA (Affinity BioReagents #
MA3-018), Mouse α-Ubiquitin (Enzo, #ADI-SPA-203-F), and Rabbit α-K48 linkage
specific polyubiquitin (Cell Signaling, #8081S), and Rabbit α-VAPA (Proteintech,
#15275-1-AP). His-Ubiquitin (# U-530), USP2 (#E-506), and USP30 (# E-582) purified
proteins and TUBEs agarose (#AM-130) were purchased from Boston Biochem.
Detergents were purchased as follows: Digitonin (EMD Millipore, Billerica, MA), Triton
X-100 (Thermo Fisher), Sodium Deoxycholate (Sigma), and Sodium Dodecyl Sulfate
(Sigma), Saponin (Sigma), 37% Formaldehyde (Avantor), and Hoechst 33342 stain (Cell
Signaling # 4082S), Tween 20 (American Bioanalytical).

6.3: In vitro translation and ubiquitination
In vitro transcription and translation were performed using the previous protocols
with the following modifications (Mariappan et al., 2010; Sharma et al., 2010). For in
vitro transcription reactions, the PCR products encoding N-terminally FLAG-tagged TA
proteins were used as templates. The PCR products were amplified from either pcDNA
3.1 or pcDNA5/FRT/TO TA protein constructs using the 5’ primer that includes the Sp6
promoter sequence and anneals to the CMV promoter and the 3’ primer that anneals to
the poly(A) tail. In vitro transcription was carried out using SP6 polymerase (NEB) and
RNase Inhibitor (Promega) at 40°C for 1.5h. The transcription reaction products were
directly added to in vitro translation reactions containing a mixture of hemin, nuclease
treated RRL, S35 methionine (PerkinElmer #NEG009T005MC), and 10 µM His-tagged
ubiquitin (Boston Biochem) and incubated for 40 minutes at 32°C. In some reactions,
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recombinant zebrafish TRC40, purified from E. coli as described previously (Mariappan
et al., 2010), was included during translations. The translation was terminated by either
adding 1mM puromycin or removing ribosomes by centrifugation at 70,000 rpm in the
TLA 120.1 rotor for 30 min. 2µL of crude microsomes prepared from HEK293 cells as
described in (Sundaram et al., 2017) was added to 20µL translation reactions and further
incubated for 30 min at 32°C. The reactions were diluted to 0.1% SDS with the Triton
buffer (50 mM Tris-HCl, 1% Triton X-100, and 150 mM NaCl) and incubated with either
20µL of Talon beads to capture ubiquitin-conjugated TA proteins or 12µL of anti-FLAG
beads (Bio-Legend) to capture FLAG-tagged TA proteins. After incubation for 1.5h at
4°C, the beads were washed 3X with 1mL of Triton buffer and eluted with 50µL of 2X
SDS sample buffer by boiling for 5min at 95°C. The eluted samples were resolved in
either 7.5% Tris-Tricine gel for ubiquitin-conjugated TA proteins or 10% Tris-Tricine gel
for total TA proteins and processed for autoradiography.

6.4: Cell culture and generating knockout cells using CRISPR/Cas9
HEK293- Flp-In™ T-REx™ 293 and HeLa T-REx™ (Thermo Fisher), and
HEK293T cell lines were cultured with high glucose DMEM (Corning, Corning, NY),
10% FBS (Gibco, Gaithersburg, MD), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Gibco) at 37°C and 5% CO2. HEK 293-Flp-In T-Rex cells were used for
generating SGTA-/-, BAG6-/- cells, USP19-/-, USP30-/-, USP20-/-, USP33-/-, and
USP20/33-/-, while HEK293T cells were used for making the partial knockout of CAML.
The knockout cell lines were generated using the CRISPR/Cas9 system as previously
described (Mali et al., 2013; Ran et al., 2013). Cells were transfected with pSpCas9(BB)2A-Puro and gRNA expression plasmid targeting SGTA (Targeting sequence:
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5’CTTGTATGTCTCGTTGTCG 3’), BAG6 (Targeting sequence:
5’CCATACCGAGGTGGCGGTC 3’), CAML (Targeting sequence:
5’TGGCCGTCGCTACCGACGG 3’), USP30 (Targeting sequence:
5’CGCTCATCTTCCAATGACG3’), USP19 (Targeting sequence
5’GAGCAAGGATGGAGATCCT 3’), USP20 (Targeting sequence:
5’GAGGTTCTTCATGCCCGTG 3’), or USP33 (Targeting sequence:
5’GCGAAGCATATGCTCCACA 3’). The transfected cells were grown for 24h and
treated with 2.5 µg/mL puromycin for 72h to select the successfully transfected clones.
Single-cell clones were isolated by plating at 0.5 cells/well in 96 well plates. All
knockouts were confirmed by immunoblotting. For generating knockout of both USP20
and USP33, pSpCas9(BB)-2A-Puro (Addgene #62988) was co-transfected with USP20
and USP33 gRNAs and followed the procedure as outlined above. For Fig. 9D,
HEK293T cells were transfected with pcDNA 3.1/FLAG-β-VAMP2. Cells stably
expressing β-VAMP2 were selected by treating with zeocin (300µg/mL) for three weeks.
The individual clones were manually picked and the expression of the β-VAMP2 was
analyzed by immunoblotting.

6.5: Immunoprecipitation of ubiquitinated TA proteins from cells
To examine the polyubiquitination of TA proteins, HEK293 cells (0.75 x
106/well) were plated on polylysine-coated (0.15 mg/mL) 6-well plates and transiently
transfected with 0.75µg pCDNA3/HA-Ubiquitin plasmid, 1.25µg of the indicated TA
constructs, and 5µL of Lipofectamine 2000 (Invitrogen) mixed in Opti-MEM (Gibco). 24
hours after transfection, cells were harvested in RIPA buffer containing 50mM Tris-HCl
pH 8.0, 150mM NaCl, 0.1% SDS, 0.5% Sodium Deoxycholate (Millipore Sigma), 1x
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cOmplete protease inhibitor cocktail (Millipore Sigma), 1mM EDTA (American Bio),
and 2mM NEM (Sigma). After centrifugation at 20,000g for 10 min, the lysates were
incubated with rat anti-FLAG beads (BioLegend) for 1.5h. The beads were then washed
with 1mL of RIPA buffer 3 times. The washed beads were directly boiled with 50µL 2x
SDS sample buffer for 5 minutes followed by immunoblotting with anti-HA for
ubiquitin-modified TA proteins and anti-FLAG antibodies for TA proteins.
In some experiments, cells were treated with 200µg/mL of cycloheximide (CHX), 20µM
MG132, or both, as indicated in the figure legends, before harvesting the cells with RIPA
buffer. In some experiments, the transfected cells were rinsed on a plate with 1XPBS and
then incubated for 10 min at 4°C in 0.5mL of 50mM HEPES, 150mM NaCl, 0.01%
digitonin, 2mM NEM, and 1x cOmplete protease inhibitor cocktail. This served as the
cytosolic fraction. The cells were rinsed once with the same buffer to further remove
cytosolic proteins and then scraped off the plate using 1mL of RIPA buffer for a crude
membrane fraction. The samples were centrifuged to remove cellular debris, and the
cytosolic fraction was made up to 1mL using RIPA buffer. The two fractions were
immunoprecipitated as above. For the endogenous TRC40 immunoprecipitation shown in
Fig. 13A and 13B, the cells were harvested in 1XPBS and centrifuged at 10,000g for 2
min. The cell pellets were lysed with 1mL of lysis buffer (50mM Tris-HCl pH 7.4,
150mM NaCl, and 0.05% digitonin, 2mM NEM, and 1X protease inhibitor) and brief
vortexing. The samples were centrifuged at 20,000g for 10 min and the pellets were
discarded. The samples were either incubated with anti-TRC40 antibodies or anti-GFP
antibodies for 1.5h at 4°C. The antibodies were recovered using Protein A agarose
(RepliGen, Waltham) for 1h at 4°C. The beads were washed 3X with 1mL of lysis buffer
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without protease inhibitor or NEM. The washed beads were resuspended in 50µL of SDS
sample buffer, boiled for 5 min at 95°C, and analyzed by immunoblotting for the
indicated antigens in the figure legends.

6.6: Metabolic labeling and immunoprecipitation
HEK 293 cells (0.75 x 106/well) were plated on polylysine coated (0.15mg/mL) 6well plates and transiently transfected with 2µg of indicated plasmids using 5µL of
Lipofectamine 2000 (Invitrogen). For metabolic labeling, cells were incubated in
cysteine- and methionine-free media with 10% dialyzed FBS for 30 min. Then, cells were
labeled with 80µCi/mL Express35S Protein Labeling Mix (PerkinElmer
#NEG072014MC) for 30 min unless otherwise indicated in the figure legends. Cells were
rinsed with 1XPBS and chased with complete DMEM medium supplemented with 2mM
Methionine and 2mM Cysteine. The labeled cells were directly harvested in 1mL of
RIPA buffer for Fig. 8D and 14A and immunoprecipitated using anti-FLAG beads. For
Fig. 8A, 15B, 22A, and 20 the labeled cells were permeabilized with 0.01-0.015%
digitonin and fractionated into cytosol and membrane fractions as described above and
immunoprecipitated using anti-FLAG beads. The immunoprecipitants were analyzed by
SDS-PAGE autoradiography.

6.7: Isolation of endogenous ubiquitinated proteins
Endogenous TRC40-interacting proteins were purified for Fig. 13C by harvesting
2x15cm plates of HEK293 cytosol via the digitonin buffer (50mM Tris-HCl pH 7.4,
150mM NaCl, and 0.015% digitonin, 2mM NEM, and 1X protease inhibitor). The
cytosol samples were incubated with ~100µL of protein A agarose beads conjugated to
either Rabbit α-TRC40 or control Rabbit α-RFP antibodies for 1.5h at 4°C. The beads
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were thoroughly washed 5 times in 0.015% digitonin. Then, 800µL of Triton X-100
buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, and 1% Triton X-100) was used to elute
proteins bound to TRC40 via hydrophobic interactions. The elutions were precipitated
using trichloroacetic acid and solubilized in 2x SDS sample buffer. For Fig. 22B, one
15cm plate of either confluent HEK293 or USP20/33-/- cells were harvested and lysed
with 1mL of lysis buffer (50mM Tris-HCl pH 7.4, 200mM NaCl, and 1% Triton X-100,
2mM NEM, 10mM iodoacetic acid, and 1X protease inhibitor). After centrifugation at
20,000g for 20min at 4°C, the supernatant was incubated with either 40µL slurry of
Strep-Tactin agarose (IBA) as a control or TUBEs agarose (Boston Biochem) for 1.5h at
4°C. The beads were washed 3x with 1mL of 50mM Tris-HCl pH 7.4, 200mM NaCl, and
1% Triton X-100. The bound proteins were boiled in 60µL of 2x SDS sample buffer and
analyzed by immunoblotting.

6.8: Purification of recombinant USP20
5 million HEK293 cells were plated on a polylysine coated (0.15mg/mL) 10 cm
plate and transiently transfected with 12µg of either His-Strep USP20 or USP20 (CH/SQ)
plasmid using 72µL of polyethylenimine (PEI) (Polysciences, Inc.) (a gift from Dr.
Fabian Giska). After 48h of transfection, cells were harvested and lysed with 1mL of
lysis buffer (50mM Tris-HCl pH 7.4, 200mM NaCl, and 0.5% Triton X-100, and 1X
protease inhibitor). After centrifugation at 20,000g for 20min, the supernatant was
incubated with 200µL of Strep-Tactin-XT beads (IBA) for 30min at 37°C. The beads
were washed 5x with 1mL of lysis buffer without protease inhibitor on a 2mL column.
The bound proteins were incubated with 200µL of lysis buffer containing 50mM Biotin
for 5min and eluted using gravity flow. The elutions were repeated two more times and
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analyzed along with BSA by Coomassie blue staining. The proteins were quantified using
Image J relative to a known concentration of BSA.

6.9: Deubiquitinase and Endo H treatments
The Endo H digestions for Fig. 15A, 21A, and 9A were performed after the
indicated proteins were immunoprecipitated and boiled in SDS buffer for 5 min. The
eluted samples were mixed with an equal volume of 1XGlycobuffer 5 (NEB)
supplemented with 2% Triton X-100 and incubated without or with Endo H for 6h at
37°C. The reactions were directly boiled with an equal volume of 3X SDS sample buffer
and analyzed by immunoblotting. For Fig. 13C, the elution from the α-TRC40 beads was
split into two equal parts. One aliquot was kept on ice and the other was incubated with
138nM of USP2 with shaking at 37°C for 2 hours and then TCA precipitated as described
above. TUBEs agarose bound endogenous ubiquitinated proteins were prepared for Fig.
22C as above. A final wash was performed with 1mL of DUB buffer (50mM Tris-HCl
pH 7.4, 50mM NaCl, 10% glycerol, 5mM DTT, and 0.1% Triton X-100). The beads were
then incubated with 200nM of USP2 with shaking at 37°C for 2 hours. The reactions
were then adjusted to 2x SDS sample buffer and boiled for 5min before analyzing by
immunoblotting. For Figure 10D, VAPA was immunoprecipitated from the cytosol
fraction using α-FLAG beads. Before boiling, the immunoprecipitants were washed once
with DUB buffer and treated with 200nM of USP2 or USP30 catalytic domain as
indicated for 2 hours at 37°C with shaking. The reactions were then adjusted to 2X SDS
sample and boiled before analyzing by autoradiography. For Fig. 22A,
Immunoprecipitated VAPA from the cytosol fraction was incubated with the increasing
concentration of either purified WT USP20 or USP20 (CH/SQ) for 35min at 37°C with
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shaking. The reactions were terminated by boiling with 2X SDS sample buffer and
analyzed by autoradiography.

6.10: Immunoblotting
Samples were run on either 10% or 7.5% Acrylamide Tris-Tricine SDS-PAGE
gels at 100v for 1.5h. The proteins from the gels were transferred onto nitrocellulose
membranes (BioRad) using 100v for 1h. Membranes were then blocked in 1XPBS/0.1%
Tween 20 (PBST) containing 5% Milk (American Bioanalytical) for 45 min. The primary
antibodies were diluted in 5% BSA (Millipore Sigma) and incubated with the membranes
for 1.5h at ambient temperature. The membranes were washed 5x with PBST, 5min per
wash. The secondary antibody conjugated with HRP was incubated for 1h in 5% milk
and washed as above before developing with ECL. To detect HA-Ubiquitin conjugated
TA proteins, the membranes were incubated with rabbit anti-HA-HRP antibody (Cell
Signaling) prepared in 5% BSA/PBST for 3h at 4°C. The antibody can be stored at -20°C
and used multiple times. After a final wash cycle, membranes were blotted dry and
incubated in Perce ECL Western Blotting Substrate, SuperSignal West Pico, or Femto
Substrate (Thermo Scientific) for 4 min and finally exposed onto HyBlot autoradiography
films (Denville). The program ImageJ (NIH) was used to quantify the intensity of bands
from the films.

6.11: Microscopy
HEK293- Flp-In™ T-REx™ 293 WT, USP20-/-, or USP33-/- cells were grown
on polylysine-coated glass microscope slides. The cells were rinsed once with PBS and
then fixed for 5 minutes with 3.7% formaldehyde in PBS. The fixed cells were rinsed
twice with PBS and then permeabilized with 0.1% Triton X-100 in PBS. Cells were
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rinsed twice in PBS with 10% FBS and 0.01% saponin and then blocked for 1h in
PBS/FBS/saponin. The HEK cells were incubated for 1h with 1:100 dilution of Mouse αUSP33 and Rabbit α-Calreticulin or Rabbit α-USP20 and Mouse α-PDIA in
PBS/FBS/saponin. Cells were washed 5x for 5min per wash. Cells were stained with a
combination of Goat α-Mouse IgG-Cy2 (Jackson ImmunoResearch # 115-225-166) and
Goat α-Rabbit IgG-Cy3 (Jackson ImmunoResearch # 111-165-003) for
USP33/Calreticulin or Goat α-Rabbit IgG-Cy2 (Jackson ImmunoResearch # 111-225144) and Goat α-Mouse IgG-Cy3 (Jackson ImmunoResearch # 115-165-003) for
USP20/PDI at 1:100 dilution in PBS/FBS/saponin all while covered to protect the
fluorophores from excess light. The cells were washed 5x again. Cells were rinsed once
with PBS and nuclei were stained using Hoechst 33342 stain (Cell Signaling # 4082S) in
PBS for 15min. Cells were washed 5x with PBS, and the cover slips were mounted onto
slides with Fluoromount G (SouthernBiotech # 0100-01). The mounting was allowed to
set overnight at 4°C while covered. HeLa T-REx™ cells were treated similar as above
with a few changes. Strep-USP33 or Strep-USP20 was transfected along with the ER
control PDI-FLAG into cells by Lipofectamine 2000 (Invitrogen). Rat α-FLAG and
either Mouse α-USP33 or Rabbit α-USP20 were used as primaries followed by staining
with Goat α-RAT IgG-Cy2 (Jackson ImmunoResearch # 112-225-167) and either Goat αMouse IgG-Alexa657 (Invitrogen # A-21235) or Goat α-Rabbit IgG-Alexa647(Invitrogen
# A27040). Confocal microscopy was performed on the slides using the Leica SP8
DMI6000 Confocal Microscope with a 63x oil objective, 1.40 aperture, and a PMT
detector. Lasers at 405, 488, 561, and 633 nm wavelength were used to excite the
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Hoechst, Cy2, Cy3, and Alexa647 respectively. Leica’s LAS X software was used to
capture and edit the gain, contrast, color, and scale bars of the images.

Sources
Art for scissors in Figure 5: http://clipart-library.com/clipart/LTdjRjeyc.htm
Mitochondria drawing: https://www.istockphoto.com/vector/vector-diagram-ofmitochondria-cross-section-view-medical-infographics-gm1166599563-321416137
ER drawing: https://www.rndsystems.com/resources/cellmarkers/organelles/organelles/organelles-endoplasmic-reticulum
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